Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Achondroplasia
Natriuretic Peptide Expression and Function in GH3 Somatolactotropes and Feline Somatotrope Pituitary Tumours.
Achondroplasia
Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.
Acidosis
Endothelin and nitric oxide mediate adaptation of the cortical collecting duct to metabolic acidosis.
Acidosis
Nitric oxide from perivascular nerves modulates cerebral arterial pH reactivity.
Acute Coronary Syndrome
Role of epicardial adipose tissue NPR-C in acute coronary syndrome.
Acute Kidney Injury
C-type natriuretic peptide ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis and oxidative stress in rats.
Acute Kidney Injury
Disruption of guanylyl cyclase-G protects against acute renal injury.
Acute Kidney Injury
Investigation of the role of nitric oxide/soluble guanylyl cyclase pathway in ascorbic acid-mediated protection against acute kidney injury in rats.
Acute Kidney Injury
L-arginine as a therapeutic tool in kidney disease.
Acute Kidney Injury
Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats.
Acute Kidney Injury
Urodilatin, not nitroprusside, combined with dopamine reverses ischemic acute renal failure.
Acute Lung Injury
Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A.
Acute Lung Injury
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Acute Lung Injury
Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.
Acute Lung Injury
The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease.
Adenocarcinoma
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Adenocarcinoma
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Adenocarcinoma
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Adenocarcinoma
Heterogeneous localization of adenylate and guanylate cyclases in R3230AC rat mammary adenocarcinoma cells.
Adenocarcinoma
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
Adenocarcinoma
Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).
Adenocarcinoma
Pathological staging and therapy of oesophageal and gastric cancer.
Adenocarcinoma
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Adenocarcinoma
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-label, Non-randomized Phase 1 Study.
Adenoma
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Adrenal Gland Neoplasms
Guanyl cyclase activity in normal adrenals and a corticosterone producing adrenal cancer of the rat.
Adrenocortical Carcinoma
Adrenocorticotropin-dependent particulate guanylate cyclase in rat adrenal and adrenocortical carcinoma: comparison of its properties with soluble guanylate cyclase and its relationship with ACTH-induced steroidogenesis.
Adrenocortical Carcinoma
Characterization and regulation by protein kinase C of renal glomerular atrial natriuretic peptide receptor-coupled guanylate cyclase.
Adrenocortical Carcinoma
Characterization of atrial-natriuretic-factor-receptor-coupled membrane guanylate cyclase from rat and mouse testes.
Adrenocortical Carcinoma
Demonstration of ACTH-sensitive particulate guanylate cyclase in adrenocortical carcinoma.
Adrenocortical Carcinoma
Dual regulation of adenylate cyclase and guanylate cyclase: alpha 2-adrenergic signal transduction in adrenocortical carcinoma cells.
Adrenocortical Carcinoma
Inhibition of alpha 2-adrenergic receptor-mediated cyclic GMP formation by a phorbol ester, a protein kinase C activator.
Adrenocortical Carcinoma
Negative regulation of atrial natriuretic factor receptor coupled membrane guanylate cyclase by phorbol ester. Potential protein kinase C regulation of cyclic GMP signal in isolated adrenocortical carcinoma cells of rat.
Adrenocortical Carcinoma
Ubiquitous and bifunctional 180 kDa atrial natriuretic factor-dependent guanylate cyclase.
Albuminuria
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Alcohol-Related Disorders
Augmented Stress-Induced Alcohol Drinking and Withdrawal in Mice Lacking Functional Natriuretic Peptide-A Receptors.
Alopecia
Guanylate cyclase activity in male pattern baldness. Stimulating effect of 3-beta-androstanediol.
Alzheimer Disease
Post-Transcriptional Regulation of Soluble Guanylate Cyclase that Governs Neuropathic Pain in Alzheimer's Disease.
Alzheimer Disease
Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains.
Alzheimer Disease
Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease.
Anaphylaxis
Methylene blue for clinical anaphylaxis treatment: a case report.
Anemia, Sickle Cell
Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
Anemia, Sickle Cell
Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
Aortic Aneurysm
Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm.
Arrhythmias, Cardiac
The Relationship between Estrogen and Nitric Oxide in the Prevention of Cardiac and Vascular Anomalies in the Developing Zebrafish (Danio Rerio).
Asthma
An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling.
Asthma
Carnosine as a regulator of soluble guanylate cyclase.
Asthma
Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction.
Asthma
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Asthma
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Asthma
NO-sensitive guanylyl cyclase in the lung.
Asthma
Response of lymphocyte guanyl cyclase to propranolol, noradrenaline, thymoxamine, and acetylcholine in extrinsic bronchial asthma.
Asthma
Review - Nutraceuticals Can Target Asthmatic Bronchoconstriction: NADPH Oxidase-Dependent Oxidative Stress, RhoA and Calcium Dynamics.
Asthma
Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma.
Asthma
Soluble guanylyl cyclase expression is reduced in allergic asthma.
Asthma
Soluble guanylyl cyclase is reduced in airway smooth muscle cells from a murine model of allergic asthma.
Asthma
The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease.
Astrocytoma
Mechanism of potentiation of LY83583-induced growth inhibition by sodium nitroprusside in human brain tumor cells.
Astrocytoma
Methylene blue induces cytotoxicity in human brain tumor cells.
Astrocytoma
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Astrocytoma
The effect of unsaturated fatty acids on sodium nitroprusside stimulation of guanylate cyclase in the human astrocytoma clone, D384, and the human neuroblastoma clone, NB1-G.
Astrocytoma
The generation of nitric oxide participates in gamma IFN-induced MHC class II antigen expression by cultured astrocytoma cells.
Ataxia
Involvement of the alpha4beta2 nicotinic receptor subtype in nicotine-induced attenuation of delta9-THC cerebellar ataxia: role of cerebellar nitric oxide.
Atherosclerosis
Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis.
Atherosclerosis
Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet-fed rabbits.
Atherosclerosis
Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
Atherosclerosis
Cygnets: in vivo characterization of novel cGMP indicators and in vivo imaging of intracellular cGMP.
Atherosclerosis
High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase.
Atherosclerosis
Long-lasting cyclic guanosine-3',5'-monophosphate accumulation in the medium of cultured smooth muscle cells from atherosclerotic rabbit aortas in response to exogenous or endogenous nitric oxide.
Atherosclerosis
Role of sGC-dependent NO signalling and myocardial infarction risk.
Atherosclerosis
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis.
Atherosclerosis
YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
Blindness
A nonsense mutation in the retinal specific guanylate cyclase gene is the cause of Leber congenital amaurosis in a large inbred kindred from Jordan.
Blindness
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
Blindness
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
Blindness
Activation of retinal guanylyl cyclase RetGC1 by GCAP1: stoichiometry of binding and effect of new LCA-related mutations.
Blindness
Bicarbonate and Ca(2+) Sensing Modulators Activate Photoreceptor ROS-GC1 Synergistically.
Blindness
Complete abolition of the retinal-specific guanylyl cyclase (retGC-1) catalytic ability consistently leads to leber congenital amaurosis (LCA).
Blindness
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.
Blindness
Different functional outcome of RetGC1 and RPE65 gene mutations in Leber congenital amaurosis.
Blindness
Dimerization Domain of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Is an Essential Part of Guanylyl Cyclase-activating Protein (GCAP) Binding Interface.
Blindness
Evaluating the Role of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Domains in Binding Guanylyl Cyclase-activating Proteins (GCAPs).
Blindness
Evidence of a founder effect for the RETGC1 (GUCY2D) 2943DelG mutation in Leber congenital amaurosis pedigrees of Finnish origin.
Blindness
Experimental Approaches for Defining the Role of the Ca
Blindness
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
Blindness
First 3D-Structural Data of Full-Length Guanylyl Cyclase 1 in Rod-Outer-Segment Preparations of Bovine Retina by Cross-Linking/Mass Spectrometry.
Blindness
Functional analyses of mutant recessive GUCY2D alleles identified in Leber congenital amaurosis patients: protein domain comparisons and dominant negative effects.
Blindness
Functional consequences of a rod outer segment membrane guanylate cyclase (ROS-GC1) gene mutation linked with Leber's congenital amaurosis.
Blindness
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Blindness
GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness.
Blindness
Insights gained from gene therapy in animal models of retGC1 deficiency.
Blindness
Insights into the role of RD3 in guanylate cyclase trafficking, photoreceptor degeneration, and Leber congenital amaurosis.
Blindness
Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness.
Blindness
Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy.
Blindness
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
Blindness
RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis 12.
Blindness
RD3, the protein associated with Leber congenital amaurosis type 12, is required for guanylate cyclase trafficking in photoreceptor cells.
Blindness
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Blindness
Regulation of retinal membrane guanylyl cyclase (RetGC) by negative calcium feedback and RD3 protein.
Blindness
Retinal diseases linked with photoreceptor guanylate cyclase.
Blindness
Retinal guanylyl cyclase activation by calcium sensor proteins mediates photoreceptor degeneration in an rd3 mouse model of congenital human blindness.
Blindness
Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis.
Blindness
Spectrum of retGC1 mutations in Leber's congenital amaurosis.
Blindness
The R838S Mutation in Retinal Guanylyl Cyclase 1 (RetGC1) Alters Calcium Sensitivity of cGMP Synthesis in the Retina and Causes Blindness in Transgenic Mice.
Blindness
Two clusters of surface-exposed amino acid residues enable high-affinity binding of retinal degeneration-3 (RD3) protein to retinal guanylyl cyclase.
Blindness
Variants at codon 838 in the GUCY2D gene result in different phenotypes of cone rod dystrophy.
Bone Resorption
C-type natriuretic peptide increases bone resorption in 1,25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures.
Bone Resorption
Oral administration of soluble guanylate cyclase agonists to rats results in osteoclastic bone resorption and remodeling with new bone formation in the appendicular and axial skeleton.
Bradycardia
Nitric oxide in the insular cortex modulates baroreflex responses in a cGMP-independent pathway.
Brain Diseases
Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery.
Brain Edema
Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema Formation after Traumatic Brain Injury.
Brain Injuries
Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema Formation after Traumatic Brain Injury.
Brain Injuries, Traumatic
Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema Formation after Traumatic Brain Injury.
Brain Ischemia
Nitric oxide production during focal cerebral ischemia in rats.
Brain Neoplasms
Guanylate cyclase in human brain tumors: regulation of cellular growth.
Brain Neoplasms
Mechanism of potentiation of LY83583-induced growth inhibition by sodium nitroprusside in human brain tumor cells.
Brain Neoplasms
Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels.
Brain Neoplasms
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Breast Neoplasms
Differential expression of alternative transcripts of soluble guanylyl cyclase, GYCY1a3 and GUCY1b3 genes, in the malignant and benign breast tumors.
Breast Neoplasms
EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase.
Breast Neoplasms
Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.
Breast Neoplasms
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Breast Neoplasms
Soluble guanylate cyclase isoenzymes: The expression of ?1, ?2, ?1, and ?2 subunits in the benign and malignant breast tumors.
Bronchial Hyperreactivity
Inhibition of guanylyl cyclase in the airways hyperreactivity.
CADASIL
Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO/sGC/cGMP pathway.
Carcinogenesis
Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Carcinogenesis
Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.
Carcinogenesis
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Carcinogenesis
Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate.
Carcinogenesis
Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.
Carcinogenesis
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Carcinogenesis
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.
Carcinogenesis
Hydrazine activation of guanylate cyclase: potential application to tobacco carcinogenesis.
Carcinogenesis
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Carcinogenesis
Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier.
Carcinogenesis
Modulation of rat guanylate cyclase activity in vitro by chemical carcinogens.
Carcinogenesis
Natriuretic peptide receptor A as a novel target for cancer.
Carcinogenesis
Saccharin inhibits guanylate cyclase activity: possible relationship to carcinogenesis.
Carcinogenesis
Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.
Carcinogenesis
[Disordered regulation of cell membrane adenyl cyclase and guanyl cyclase activity as a possible factor in carcinogenesis]
Carcinoma
An oxidized analog of alpha-human atrial natriuretic polypeptide is a selective agonist for the atrial-natriuretic-polypeptide clearance receptor which lacks a guanylate cyclase.
Carcinoma
Characterization of the synergistic interaction of Escherichia coli heat-stable toxin and carbachol.
Carcinoma
Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.
Carcinoma
Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.
Carcinoma
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.
Carcinoma
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Carcinoma
Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix.
Carcinoma
GCAP-II: isolation and characterization of the circulating form of human uroguanylin.
Carcinoma
Guanylate Cyclase Activator YC-1 Enhances TRAIL-Induced Apoptosis in Human Epithelial Ovarian Carcinoma Cells via Activation of Apoptosis-Related Proteins.
Carcinoma
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Carcinoma
Guanylate cyclase activity in normal and neoplastic squamous epithelia from the upper aero-digestive tract.
Carcinoma
Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.
Carcinoma
Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.
Carcinoma
Interaction of guanylyl cyclase C with SH3 domain of Src tyrosine kinase. Yet another mechanism for desensitization.
Carcinoma
Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells.
Carcinoma
Involvement of protein kinase C in the mechanism of action of Escherichia coli heat-stable enterotoxin (STa) in a human colonic carcinoma cell line, COLO-205.
Carcinoma
Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors.
Carcinoma
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Carcinoma
Negative regulation of atrial natriuretic factor receptor coupled membrane guanylate cyclase by phorbol ester. Potential protein kinase C regulation of cyclic GMP signal in isolated adrenocortical carcinoma cells of rat.
Carcinoma
Nitric oxide pathways in human bladder carcinoma. The distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine.
Carcinoma
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Carcinoma
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
Carcinoma
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Carcinoma
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-label, Non-randomized Phase 1 Study.
Carcinoma
The beta(2) subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma.
Carcinoma
The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin.
Carcinoma
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Carcinoma, Hepatocellular
Guanyl cyclase activity in Morris hepatomas. 7787, 7795, 7800 and 9618A-2.
Carcinoma, Hepatocellular
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Carcinoma, Hepatocellular
Increased particulate and decreased soluble guanylate cyclase activity in regenerating liver, fetal liver, and hepatoma.
Carcinoma, Hepatocellular
Pancreastatin, a chromogranin A-derived peptide, inhibits DNA and protein synthesis by producing nitric oxide in HTC rat hepatoma cells.
Carcinoma, Hepatocellular
Properties of guanylate cyclase in adult rat liver and several Morris hepatomas.
Carcinoma, Hepatocellular
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Carcinoma, Medullary
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Carcinoma, Non-Small-Cell Lung
Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2.
Carcinoma, Non-Small-Cell Lung
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Carcinoma, Ovarian Epithelial
Guanylate Cyclase Activator YC-1 Enhances TRAIL-Induced Apoptosis in Human Epithelial Ovarian Carcinoma Cells via Activation of Apoptosis-Related Proteins.
Carcinoma, Ovarian Epithelial
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Carcinoma, Squamous Cell
Guanylate cyclase activity in normal and neoplastic squamous epithelia from the upper aero-digestive tract.
Carcinoma, Squamous Cell
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
Cardio-Renal Syndrome
Soluble guanylate cyclase: a potential therapeutic target for heart failure.
Cardiomegaly
Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A.
Cardiomegaly
Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation.
Cardiomegaly
C-type natriuretic peptide: A new cardiac mediator.
Cardiomegaly
Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.
Cardiomegaly
CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation in ANP-receptor deficient mice.
Cardiomegaly
Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.
Cardiomegaly
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Cardiomegaly
Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Cardiomegaly
Exposure to cigarette smoke abrogates the beneficial effect of ischemic postconditioning.
Cardiomegaly
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Cardiomegaly
Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.
Cardiomegaly
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Cardiomegaly
Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan.
Cardiomegaly
Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.
Cardiomegaly
Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy.
Cardiomegaly
Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.
Cardiomegaly
Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A.
Cardiomegaly
Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart.
Cardiomegaly
Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.
Cardiomegaly
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Cardiomegaly
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.
Cardiomegaly
The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A.
Cardiomegaly
Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice.
Cardiomyopathies
BAY60-2770 attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy.
Cardiomyopathies
Distinct Myocardial Mechanisms Underlie Cardiac Dysfunction in Endotoxemic Male and Female Mice.
Cardiomyopathies
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Cardiomyopathies
Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death.
Cardiomyopathies
Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy.
Cardiomyopathy, Dilated
Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death.
Cardiotoxicity
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Cardiotoxicity
Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.
Cardiotoxicity
Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.
Cardiotoxicity
Lack of correlation between effects of anthracyclines on in vitro cardiac guanyl cyclase and in vivo cardiotoxicity.
Cardiotoxicity
Selective inhibition of rat and human cardiac guanylate cyclase by doxorubicin (adriamycin): possible link to anthracycline cardiotoxicity.
Cardiotoxicity
Selective inhibition of rat and human cardiac guanylate cyclase in vitro by doxorubicin (adriamycin): possible link to anthracycline cardiotoxicity.
Cardiotoxicity
The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review.
Cardiovascular Diseases
C-type natriuretic peptide: A new cardiac mediator.
Cardiovascular Diseases
Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice.
Cardiovascular Diseases
Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.
Cardiovascular Diseases
Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide.
Cardiovascular Diseases
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans.
Cardiovascular Diseases
Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase.
Cardiovascular Diseases
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.
Cardiovascular Diseases
Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.
Cardiovascular Diseases
In vitro inactivation of mammalian methionine synthase by nitric oxide.
Cardiovascular Diseases
Molecular Model of a Soluble Guanylyl Cyclase Fragment Determined by Small-Angle X-ray Scattering and Chemical Cross-Linking.
Cardiovascular Diseases
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Cardiovascular Diseases
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Cardiovascular Diseases
NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling.
Cardiovascular Diseases
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Cardiovascular Diseases
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Cardiovascular Diseases
Soluble guanylate cyclase as a novel treatment target for osteoporosis.
Cardiovascular Diseases
Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Cardiovascular Diseases
Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.
Cardiovascular Diseases
Solution structures of the Shewanella woodyi H-NOX protein in the presence and absence of soluble guanylyl cyclase stimulator IWP-051.
Cardiovascular Diseases
Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants.
Cardiovascular Diseases
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.
Cardiovascular Diseases
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
Cardiovascular Diseases
Targeting transcriptional control of soluble guanylyl cyclase via NOTCH for prevention of cardiovascular disease.
Cardiovascular Diseases
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Cardiovascular Diseases
The impact of nitric oxide in cardiovascular medicine: untapped potential utility.
Cardiovascular Diseases
The molecular mechanism of heme loss from oxidized soluble guanylate cyclase induced by conformational change.
Cardiovascular Diseases
The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.
Cardiovascular Diseases
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
Cardiovascular Diseases
The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Cardiovascular Diseases
The Soluble Guanylyl Cyclase Activator BAY 60-2770 Ameliorates Overactive Bladder in Obese Mice.
Catalepsy
Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice.
Cerebral Infarction
[Effects of electroacupuncture "Shuigou" on expression of soluble guanylate cyclase(sGC) and protein kinase G (PKG)in vascular smooth muscle of cerebral artery in rats with cerebral infarction].
Cerebrovascular Trauma
VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway.
Cholangiocarcinoma
Guanylin regulates chloride secretion in the human gallbladder via the bile fluid.
Cholangiocarcinoma
Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.
Cholera
A simple, sensitive, and specific assay for the heat-stable enterotoxin of Escherichia coli.
Cholera
Effects of G protein and cGMP on phytochrome-mediated amaranthin synthesis inAmaranthus caudatus seedlings.
Cholera
From Escherichia coli heat-stable enterotoxin to mammalian endogenous guanylin hormones.
Cholera
Gaseous ligand selectivity of the H-NOX sensor protein from Shewanella oneidensis and comparison to those of other bacterial H-NOXs and soluble guanylyl cyclase.
Cholera
Inhibition of guanylate cyclase and cyclic GMP phosphodiesterase by cholera toxin.
Cholera
Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP.
Choriocarcinoma
Expression and function of autocrine motility factor receptor in human choriocarcinoma.
Cocarcinogenesis
Biochemical evidence of cocarcinogenesis: tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity.
Colitis
Decrease of guanylyl cyclase ?1 subunit and nitric oxide (NO)-induced relaxation in mouse rectum with colitis and its reproduction on long-term NO treatment.
Colitis
Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold.
Colitis
Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
Colitis
Influence of soluble guanylate cyclase inhibition on inflammation and motility disturbances in DSS-induced colitis.
Colitis, Ulcerative
Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.
Colonic Neoplasms
Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer.
Colonic Neoplasms
Bacterial enterotoxins are associated with resistance to colon cancer.
Colonic Neoplasms
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes.
Colonic Neoplasms
Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.
Colonic Neoplasms
Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis.
Colonic Neoplasms
Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells.
Colonic Neoplasms
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Colonic Neoplasms
Guanylyl cyclase C signaling axis and colon cancer prevention.
Colonic Neoplasms
In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties.
Colonic Neoplasms
In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Colonic Neoplasms
In vivo evaluation of an 111In-labeled ST-peptide analog for specific-targeting of human colon cancers.
Colonic Neoplasms
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
Colonic Neoplasms
Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins.
Colonic Neoplasms
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Colonic Neoplasms
Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study.
Colonic Neoplasms
Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Colonic Neoplasms
Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.
Colonic Neoplasms
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Colonic Neoplasms
Synthesis and in vitro evaluation of an 111In-labeled ST-peptide enterotoxin (ST) analogue for specific targeting of guanylin receptors on human colonic cancers.
Colonic Neoplasms
Thermodynamic analyses reveal role of water release in epitope recognition by a monoclonal antibody against the human guanylyl cyclase C receptor.
Colonic Neoplasms
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Colorectal Neoplasms
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Colorectal Neoplasms
A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel.
Colorectal Neoplasms
A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells.
Colorectal Neoplasms
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
Colorectal Neoplasms
An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Colorectal Neoplasms
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Colorectal Neoplasms
Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer.
Colorectal Neoplasms
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Colorectal Neoplasms
Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients.
Colorectal Neoplasms
Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
Colorectal Neoplasms
Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients.
Colorectal Neoplasms
Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications.
Colorectal Neoplasms
Does stage II colorectal cancer need to be redefined?
Colorectal Neoplasms
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Colorectal Neoplasms
Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Colorectal Neoplasms
Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells.
Colorectal Neoplasms
Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors.
Colorectal Neoplasms
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Colorectal Neoplasms
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Colorectal Neoplasms
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Colorectal Neoplasms
Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer.
Colorectal Neoplasms
Guanylyl cyclase C as a biomarker in colorectal cancer.
Colorectal Neoplasms
Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells.
Colorectal Neoplasms
Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Colorectal Neoplasms
Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.
Colorectal Neoplasms
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Colorectal Neoplasms
Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.
Colorectal Neoplasms
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
Colorectal Neoplasms
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Colorectal Neoplasms
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
Colorectal Neoplasms
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
Colorectal Neoplasms
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Colorectal Neoplasms
GUCY2C-targeted cancer immunotherapy: past, present and future.
Colorectal Neoplasms
Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro.
Colorectal Neoplasms
Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery.
Colorectal Neoplasms
In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers.
Colorectal Neoplasms
Intestinal GUCY2C Prevents TGF-? Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer.
Colorectal Neoplasms
Intrinsic variability in the detection of micrometastases in lymph nodes for re-staging of colorectal cancer. effect of individual markers and tissue samples.
Colorectal Neoplasms
Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer.
Colorectal Neoplasms
Molecular staging of node negative patients with colorectal cancer.
Colorectal Neoplasms
Mucosally restricted antigens as novel immunological targets for antitumor therapy.
Colorectal Neoplasms
Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
Colorectal Neoplasms
Optimizing the radiosynthesis of [68Ga]DOTA-MLN6907 peptide containing three disulfide cyclization bonds - a GCC specific chelate for clinical radiopharmaceuticals.
Colorectal Neoplasms
Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients.
Colorectal Neoplasms
Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer.
Colorectal Neoplasms
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
Colorectal Neoplasms
Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Colorectal Neoplasms
Previstage GCC Colorectal Cancer Staging Test: A New Molecular Test to Identify Lymph Node Metastases and Provide More Accurate Information about the Stage of Patients with Colorectal Cancer.
Colorectal Neoplasms
Previstage GCC test for staging patients with colorectal cancer.
Colorectal Neoplasms
Previstagetrade mark GCC test for staging patients with colorectal cancer.
Colorectal Neoplasms
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Colorectal Neoplasms
Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients.
Colorectal Neoplasms
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Colorectal Neoplasms
Relative quantification based on logistic models for individual polymerase chain reactions.
Colorectal Neoplasms
Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
Colorectal Neoplasms
Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer.
Colorectal Neoplasms
STa peptide analogs for probing guanylyl cyclase C.
Colorectal Neoplasms
Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction.
Colorectal Neoplasms
The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.
Colorectal Neoplasms
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission.
Colorectal Neoplasms
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Colorectal Neoplasms
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Colorectal Neoplasms
[Detection of guanylate cyclase C mRNA and cytokeratin 20 mRNA in peripheral blood and analysis of prognosis in early to moderate colorectal cancer patients].
Cone Dystrophy
A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1.
Cone Dystrophy
Ca(2+)-binding proteins in the retina: from discovery to etiology of human disease(1).
Cone Dystrophy
Calcium binding, structural stability and guanylate cyclase activation in GCAP1 variants associated with human cone dystrophy.
Cone Dystrophy
Calcium binding, structural stability and guanylate cyclase activation in GCAP1 variants associated with human cone dystrophy.
Cone Dystrophy
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Cone Dystrophy
Dominant cone and cone-rod dystrophies: functional analysis of mutations in retGC1 and GCAP1.
Cone Dystrophy
Dominant Cone-Rod Dystrophy: A Mouse Model Generated by Gene Targeting of the GCAP1/Guca1a Gene.
Cone Dystrophy
Functional characterization of a novel GUCA1A missense mutation (D144G) in autosomal dominant cone dystrophy: A novel pathogenic GUCA1A variant in COD.
Cone Dystrophy
Mutations in the GUCA1A gene involved in hereditary cone dystrophies impair calcium-mediated regulation of guanylate cyclase.
Cone Dystrophy
Rapid cohort generation and analysis of disease spectrum of large animal model of cone dystrophy.
Cone-Rod Dystrophies
A Gly86Arg mutation in the calcium-sensor protein GCAP1 alters regulation of retinal guanylyl cyclase and causes dominant cone-rod degeneration.
Cone-Rod Dystrophies
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
Cone-Rod Dystrophies
Autosomal dominant cone and cone-rod dystrophy with mutations in the guanylate cyclase activator 1A gene-encoding guanylate cyclase activating protein-1.
Cone-Rod Dystrophies
Autosomal dominant cone-rod dystrophy due to a missense mutation (R838C) in the guanylate cyclase 2D gene (GUCY2D) with preserved rod function in one branch of the family.
Cone-Rod Dystrophies
Autosomal dominant cone-rod dystrophy with mutations in the guanylate cyclase 2D gene encoding retinal guanylate cyclase-1.
Cone-Rod Dystrophies
Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase.
Cone-Rod Dystrophies
Biochemical analysis of a dimerization domain mutation in RetGC-1 associated with dominant cone-rod dystrophy.
Cone-Rod Dystrophies
Clustering and frequency of mutations in the retinal guanylate cyclase (GUCY2D) gene in patients with dominant cone-rod dystrophies.
Cone-Rod Dystrophies
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Cone-Rod Dystrophies
Dominant cone and cone-rod dystrophies: functional analysis of mutations in retGC1 and GCAP1.
Cone-Rod Dystrophies
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
Cone-Rod Dystrophies
Functional characterization of missense mutations at codon 838 in retinal guanylate cyclase correlates with disease severity in patients with autosomal dominant cone-rod dystrophy.
Cone-Rod Dystrophies
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Cone-Rod Dystrophies
Guanylate cyclase activating proteins, guanylate cyclase and disease.
Cone-Rod Dystrophies
GUCY2D Cone-Rod Dystrophy-6 Is a "Phototransduction Disease" Triggered by Abnormal Calcium Feedback on Retinal Membrane Guanylyl Cyclase 1.
Cone-Rod Dystrophies
GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness.
Cone-Rod Dystrophies
Impairment of the rod outer segment membrane guanylate cyclase dimerization in a cone-rod dystrophy results in defective calcium signaling.
Cone-Rod Dystrophies
Leber congenital amaurosis.
Cone-Rod Dystrophies
Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy.
Cone-Rod Dystrophies
Mutations in the rod outer segment membrane guanylate cyclase in a cone-rod dystrophy cause defects in calcium signaling.
Cone-Rod Dystrophies
Novel complex GUCY2D mutation in Japanese family with cone-rod dystrophy.
Cone-Rod Dystrophies
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy.
Cone-Rod Dystrophies
Phenotype of autosomal dominant cone-rod dystrophy due to the R838C mutation of the GUCY2D gene encoding retinal guanylate cyclase-1.
Cone-Rod Dystrophies
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
Cone-Rod Dystrophies
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Cone-Rod Dystrophies
Retinal degeneration-3 protein attenuates photoreceptor degeneration in transgenic mice expressing dominant mutation of human retinal guanylyl cyclase.
Cone-Rod Dystrophies
Retinal diseases linked with photoreceptor guanylate cyclase.
Cone-Rod Dystrophies
Spectrum of retGC1 mutations in Leber's congenital amaurosis.
Cone-Rod Dystrophies
The dimerization domain in outer segment guanylate cyclase is a Ca²?-sensitive control switch module.
Cone-Rod Dystrophies
Variants at codon 838 in the GUCY2D gene result in different phenotypes of cone rod dystrophy.
Congenital Abnormalities
An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.
Contracture
The role of the NO/NMDA pathways in the development of morphine withdrawal induced by naloxone in vitro.
Coronary Artery Disease
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Coronary Artery Disease
Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
Coronary Disease
Purification and characterization of NO-sensitive guanylyl cyclase.
Coronary Disease
[Functional activity of platelet guanylate cyclase and cardiac hemodynamics in patients with chronic heart failure and relevant changes after treatment with isosorbide-5-mononitrate]
Creutzfeldt-Jakob Syndrome
Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains.
Crohn Disease
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease.
Cryptorchidism
Tissue guanosine-3',5'-cyclic monophosphate levels and soluble guanylate cyclase activity: a positive correlation during unilateral cryptorchidism in the rat testis.
Cystic Fibrosis
Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation.
Cystic Fibrosis
C-type natriuretic peptide increases chloride permeability in normal and cystic fibrosis airway cells.
Cystic Fibrosis
Cellular effects of guanylin and uroguanylin.
Cystic Fibrosis
Cl- transport in an immortalized human epithelial cell line (NCM460) derived from the normal transverse colon.
Cystic Fibrosis
Clara cell impact in air-side activation of CFTR in small pulmonary airways.
Cystic Fibrosis
DETANO and nitrated lipids increase chloride secretion across lung airway cells.
Cystic Fibrosis
Duodenal bicarbonate secretion in rats: stimulation by intra-arterial and luminal guanylin and uroguanylin.
Cystic Fibrosis
Emerging pharmacologic therapies for irritable bowel syndrome.
Cystic Fibrosis
Guanylin and related peptides.
Cystic Fibrosis
Guanylin mRNA expression in human intestine and colorectal adenocarcinoma.
Cystic Fibrosis
Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea.
Cystic Fibrosis
Linaclotide Improves Gastrointestinal Transit in Cystic Fibrosis Mice by Inhibiting Sodium/Hydrogen Exchanger 3.
Cystic Fibrosis
Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Cystic Fibrosis
Regulation of amiloride-sensitive sodium absorption in murine airway epithelium by C-type natriuretic peptide.
Cystic Fibrosis
Regulation of intestinal gene expression by dietary zinc: induction of uroguanylin mRNA by zinc deficiency.
Cystic Fibrosis
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.
Cystic Fibrosis
Uroguanylin and guanylate cyclase C in the human pancreas: expression and mutuality of ligand/receptor localization as indicators of intercellular paracrine signaling pathways.
Cystitis
Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice.
Cystitis, Interstitial
Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
Cysts
Characterisation of guanylyl cyclase genes in the soybean cyst nematode, Heterodera glycines.
Cysts
Cyclic GMP controls Rhodospirillum centenum cyst development.
Cysts
DNA-binding properties of a cGMP-binding CRP homologue that controls development of metabolically dormant cysts of Rhodospirillum centenum.
Dehydration
Tonicity-dependent induction of Sgk1 expression has a potential role in dehydration-induced natriuresis in rodents.
Dementia
VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue afflicted by Alzheimer's disease/senile dementia of the Alzheimer type.
Diabetes Complications
Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus
Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus.
Diabetes Mellitus
Guanylate cyclase activity in rat liver and other tissues with starvation and streptozotocin-induced diabetes mellitus.
Diabetes Mellitus
Guanylate cyclase in human platelets with different aggregability.
Diabetes Mellitus
Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients.
Diabetes Mellitus
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
Diabetes Mellitus
[ADP-induced aggregation of human platelets in diabetes mellitus]
Diabetes Mellitus
[Human thrombocyte guanylate cyclase in diabetes mellitus]
Diabetes Mellitus
[Relation between human platelet aggregation and activation of soluble platelet guanylate cyclase]
Diabetes Mellitus, Experimental
Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
Diabetes Mellitus, Type 2
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Diabetes Mellitus, Type 2
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus, Type 2
Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients.
Diabetes Mellitus, Type 2
Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Diabetic Cardiomyopathies
Heart specific up-regulation of genes for B-type and C-type natriuretic peptide receptors in diabetic mice.
Diabetic Cardiomyopathies
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
Diabetic Nephropathies
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.
Diabetic Nephropathies
Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade.
Diabetic Nephropathies
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Diabetic Nephropathies
[Endothelial relaxation factor in the development of diabetic nephropathy]
Diabetic Retinopathy
Aberrant utilization of nitric oxide and regulation of soluble guanylate cyclase in rat diabetic retinopathy.
Donohue Syndrome
Decreased cyclic guanosine 3',5' monophosphate and guanylate cyclase activity in leprechaunism: evidence for a postreceptor defect.
Ductus Arteriosus, Patent
Role of cyclic nucleotides in relaxation of fetal lamb ductus arteriosus.
Dwarfism
C-type natriuretic peptide in growth: a new paradigm.
Dwarfism
Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.
Dwarfism
Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux.
Dwarfism
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Dwarfism
Prevention of guanylyl cyclase-B dephosphorylation rescues achondroplastic dwarfism.
Dwarfism
Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in lbab -/- mice.
Dysentery, Bacillary
[Prostaglandins and cyclic nucleotides in the gastrointestinal form of yersiniosis]
Dyskinesias
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Dystonia
Neurotoxicity in conscious rats following intraventricular SNAP, a nitric oxide donor.
Endotoxemia
Desensitization of soluble guanylate cyclase in renal cortex during endotoxemia in mice.
Endotoxemia
Guanylyl Cyclase A in Both Renal Proximal Tubular and Vascular Endothelial Cells Protects the Kidney against Acute Injury in Rodent Experimental Endotoxemia Models.
Endotoxemia
Nitric oxide modifies the sarcoplasmic reticular calcium release channel in endotoxemia by both guanosine-3',5' (cyclic) phosphate-dependent and independent pathways.
Endotoxemia
Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity.
Endotoxemia
Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats.
Endotoxemia
Selective inhibition of guanylate cyclase prevents impairment of hypoxic pulmonary vasoconstriction in endotoxemic mice.
Enterocolitis, Pseudomembranous
Purified Clostridium difficile cytotoxin stimulates guanylate cyclase activity and inhibits adenylate cyclase activity.
Erectile Dysfunction
A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.
Erectile Dysfunction
Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.
Erectile Dysfunction
Adenylate and guanylate cyclase activity in the penis and aorta of the diabetic rat: an in vitro study.
Erectile Dysfunction
Analysis of Erectile Responses to BAY 41-8543 and Muscarinic Receptor Stimulation in the Rat.
Erectile Dysfunction
BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo.
Erectile Dysfunction
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Erectile Dysfunction
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Erectile Dysfunction
Constitutive LH receptor activity impairs NO-mediated penile smooth muscle relaxation.
Erectile Dysfunction
Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
Erectile Dysfunction
Exploring the Potential of No-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction.
Erectile Dysfunction
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS.
Erectile Dysfunction
Hypercontractility and impaired sildenafil relaxations in the BKCa channel deletion model of erectile dysfunction.
Erectile Dysfunction
Membrane bound guanylyl cyclase as a potential molecular target for the treatment of erectile dysfunction.
Erectile Dysfunction
Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.
Erectile Dysfunction
Oral phosphodiesterase-5 inhibitors and sperm functions.
Erectile Dysfunction
Role of the soluble guanylyl cyclase alpha1-subunit in mice corpus cavernosum smooth muscle relaxation.
Erectile Dysfunction
Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction.
Erectile Dysfunction
Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.
Erectile Dysfunction
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Erectile Dysfunction
Yohimbine relaxes the human corpus cavernosum through a non-adrenergic mechanism involving the activation of K(+)ATP-dependent channels.
Esophageal Achalasia
Loss of ?1?1 Soluble Guanylate Cyclase, the Major Nitric Oxide Receptor, Leads to Moyamoya and Achalasia.
Essential Hypertension
Association of CT dinucleotide repeat polymorphism in the 5'-flanking region of the guanylyl cyclase (GC)-A gene with essential hypertension in the Japanese.
Essential Hypertension
Haplotype-based case-control study of the association between the guanylate cyclase activator 2B (GUCA2B, Uroguanylin) gene and essential hypertension.
Essential Hypertension
Soluble guanylate cyclase contribute genetic susceptibility to essential hypertension in the Han Chinese population.
Eye Diseases
Autosomal dominant cone-rod dystrophy due to a missense mutation (R838C) in the guanylate cyclase 2D gene (GUCY2D) with preserved rod function in one branch of the family.
Familial Primary Pulmonary Hypertension
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Fatty Liver
The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
Fetal Growth Retardation
Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat.
Fetal Growth Retardation
Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia.
Fetal Growth Retardation
The soluble guanylate cyclase inhibitor methylene blue evokes preterm delivery and fetal growth restriction in a mouse model.
Ganglioneuroblastoma
Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Gastrointestinal Diseases
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
Gastrointestinal Diseases
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Gastrointestinal Neoplasms
Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.
Gastrointestinal Neoplasms
Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Gastroparesis
Heme deficiency of soluble guanylate cyclase induces gastroparesis.
Gastroparesis
Natriuretic Peptide-Dependent cGMP Signal Pathway Potentiated the Relaxation of Gastric Smooth Muscle in Streptozotocin-Induced Diabetic Rats.
Glaucoma
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Glaucoma
Soluble Guanylate Cyclase ?1-Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma.
Glaucoma
Soluble Guanylate Cyclase a1-Deficient Mice: a novel murine model for Primary Open Angle Glaucoma.
Glaucoma
The Discovery of ( S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma.
Glaucoma, Open-Angle
Soluble Guanylate Cyclase ?1-Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma.
Glaucoma, Open-Angle
Soluble Guanylate Cyclase a1-Deficient Mice: a novel murine model for Primary Open Angle Glaucoma.
Glioblastoma
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Glioma
Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Glioma
Comparison of a cloned ANF-sensitive guanylate cyclase (GC-A) with particulate guanylate cyclase from adrenal cortex.
Glioma
Detection of membrane-bound guanylate cyclase activity in rat C6 glioma cells at different growth states following activation by natriuretic peptides.
Glioma
Effects of three distinct natriuretic peptides on receptor binding and guanylate cyclase activities in rat glioma cells.
Glioma
Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3.
Glioma
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.
Glioma
Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.
Glioma
Selective activation of particulate guanylate cyclase by a specific class of porphyrins.
Glioma
[Effect of GM3 ganglioside on the adenyl and guanyl cyclase activity of cultured cells]
Glomerulonephritis
Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
Glomerulonephritis
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Glomerulonephritis
Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
Glucose Intolerance
? Cell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice.
Granuloma
Guanylate cyclase in carrageenin granuloma tissue of rat.
guanylate cyclase deficiency
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
guanylate cyclase deficiency
Anaphylactic shock depends on PI3K and eNOS-derived NO.
guanylate cyclase deficiency
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.
guanylate cyclase deficiency
Gene Therapy Fully Restores Vision to the All-Cone Nrl(-/-) Gucy2e(-/-) Mouse Model of Leber Congenital Amaurosis-1.
guanylate cyclase deficiency
Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
guanylate cyclase deficiency
Insights gained from gene therapy in animal models of retGC1 deficiency.
Head Injuries, Closed
Zinc protoporphyrin IX attenuates closed head injury-induced edema formation, blood-brain barrier disruption, and serotonin levels in the rat.
Hearing Loss
Guanylyl Cyclase A/cGMP Signaling Slows Hidden, Age- and Acoustic Trauma-Induced Hearing Loss.
Heart Arrest
Protective effects of nitric oxide synthase 3 and soluble guanylate cyclase on the outcome of cardiac arrest and cardiopulmonary resuscitation in mice.
Heart Diseases
Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.
Heart Diseases
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Heart Diseases
The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
Heart Failure
?3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes.
Heart Failure
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Heart Failure
A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
Heart Failure
Acute Hemodynamic Effects of Riociguat in Patients with Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study.
Heart Failure
Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo.
Heart Failure
Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Heart Failure
Assessment of the Effects of Renal Impairment on the Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat After a Single Intravenous Dose.
Heart Failure
C-type natriuretic peptide transcriptomic profiling increases in human leukocytes of patients with chronic heart failure as a function of clinical severity.
Heart Failure
Captopril and ANP: changes in renal hemodynamics, glomerular-ANP receptors and guanylate cyclase activity in rats with heart failure.
Heart Failure
Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.
Heart Failure
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
Heart Failure
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Heart Failure
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
Heart Failure
Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
Heart Failure
Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
Heart Failure
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
Heart Failure
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice.
Heart Failure
Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure.
Heart Failure
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Heart Failure
Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Heart Failure
Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure.
Heart Failure
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Heart Failure
Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Heart Failure
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Heart Failure
Effects of an orally active NO-releasing agent, CAS 936, and its active metabolite, 3754, on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure.
Heart Failure
Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator.
Heart Failure
Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure.
Heart Failure
Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart.
Heart Failure
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Heart Failure
Gene expression of C-type natriuretic peptide and of its specific receptor NPR-B in human leukocytes of healthy and heart failure subjects.
Heart Failure
Glucocorticoids Improve Renal Responsiveness to ANP by Upregulating NPR-A Expression in the Renal Inner Medullary Collecting Duct in Decompensated Heart Failure.
Heart Failure
Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.
Heart Failure
Heart Failure With Reduced Ejection Fraction: A Review.
Heart Failure
Identification of small molecule NPR-B antagonists by high throughput screening - potential use in heart failure.
Heart Failure
Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials.
Heart Failure
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Heart Failure
Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
Heart Failure
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Heart Failure
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Heart Failure
Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction.
Heart Failure
Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats.
Heart Failure
NPR-B, the C-type natriuretic peptide specific receptor, is the predominant biological receptor in mouse and pig myocardial tissue.
Heart Failure
Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials.
Heart Failure
Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction.
Heart Failure
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
Heart Failure
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
Heart Failure
Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.
Heart Failure
Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
Heart Failure
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Heart Failure
Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure.
Heart Failure
Prevention of endothelial dysfunction in heart failure by vitamin E: attenuation of vascular superoxide anion formation and increase in soluble guanylyl cyclase expression.
Heart Failure
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Heart Failure
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
Heart Failure
Rationale and Design of the VITALITY-HFpEF Trial.
Heart Failure
Renal Ca2+ + Mg2+ ATPase in congestive heart failure due to diabetes.
Heart Failure
Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.
Heart Failure
Role of guanylate cyclase modulators in decompensated heart failure.
Heart Failure
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Heart Failure
Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Heart Failure
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Heart Failure
Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure.
Heart Failure
Soluble guanylate cyclase modulators in heart failure.
Heart Failure
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Heart Failure
Soluble guanylate cyclase: a potential therapeutic target for heart failure.
Heart Failure
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Heart Failure
Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling.
Heart Failure
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
Heart Failure
The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Heart Failure
The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
Heart Failure
Treatment of Heart Failure with Preserved Ejection Fraction.
Heart Failure
Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure.
Heart Failure
Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones.
Heart Failure
Updates in pharmacotherapy of heart failure with reduced ejection fraction.
Heart Failure
Vericiguat for Heart Failure with Reduced Ejection Fraction.
Heart Failure
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Heart Failure
Vericiguat in patients with heart failure and reduced ejection fraction.
Heart Failure
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Heart Failure
Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
Heart Failure
Vericiguat: First Approval.
Heart Failure
Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure.
Heart Failure
[Functional activity of platelet guanylate cyclase and cardiac hemodynamics in patients with chronic heart failure and relevant changes after treatment with isosorbide-5-mononitrate]
heme oxygenase (biliverdin-producing) deficiency
Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.
Hepatic Encephalopathy
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.
Hepatitis
Altered modulation of soluble guanylate cyclase by nitric oxide in patients with liver disease.
Hepatitis
Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease.
Hepatitis A
Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.
Hepatopulmonary Syndrome
Methylene blue improves the hepatopulmonary syndrome.
Hernias, Diaphragmatic, Congenital
Nitric oxide activity through guanylate cyclase and phosphodiesterase modulation is impaired in fetal lambs with congenital diaphragmatic hernia.
Hernias, Diaphragmatic, Congenital
The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model.
Herpes Zoster
Development of p-benzoylbenzoylated [N,C,rANP(1-28)]pBNP32 (pBNP1) derivatives and affinity photolabeling of the bovine NPR-A receptor.
Herpes Zoster
Differential regional expression of three natriuretic peptide receptor genes within primate tissues.
Herpes Zoster
Downregulation of adrenal atrial natriuretic peptide receptor mRNAs and proteins by pregnancy in rats.
Herpes Zoster
Phosphorylation of atrial natriuretic factor R1 receptor by serine/threonine protein kinases: evidences for receptor regulation.
Herpes Zoster
Purification and characterization of two types of atrial natriuretic factor receptors from bovine adrenal cortex: guanylate cyclase-linked and cyclase-free receptors.
Herpes Zoster
Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats.
Herpes Zoster
Vascular Endothelial Growth Factors and vascular permeability.
Hyperalgesia
Activation and up-regulation of spinal cord nitric oxide receptor, soluble guanylate cyclase, after formalin injection into the rat hind paw.
Hyperalgesia
Characterization of nociceptin hyperalgesia and allodynia in conscious mice.
Hyperalgesia
Choline attenuates inflammatory hyperalgesia activating nitric oxide/cGMP/ATP-sensitive potassium channels pathway.
Hyperalgesia
Differential effects of intrathecally and intracerebroventricularly administered nitric oxide donors on noxious mechanical and thermal stimulation.
Hyperalgesia
Dual effect of local application of nitric oxide donors in a model of incision pain in rats.
Hyperalgesia
Glycinergic mediation of tactile allodynia induced by platelet-activating factor (PAF) through glutamate-NO-cyclic GMP signalling in spinal cord in mice.
Hyperalgesia
Inhibition of inducible nitric oxide synthase in persistent pain.
Hyperalgesia
Involvement of endogenous nitric oxide in the mechanism of bradykinin-induced peripheral hyperalgesia.
Hyperalgesia
Involvement of glutamate receptors in strychnine- and bicuculline-induced allodynia in conscious mice.
Hyperalgesia
Nitric oxide (NO) and nociceptive processing in the spinal cord.
Hyperalgesia
Nitric oxide mediates allodynia induced by intrathecal administration of prostaglandin E2 or prostaglandin F2 alpha in conscious mice.
Hyperalgesia
Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat.
Hyperalgesia
Nitric oxide signaling in pain and nociceptor sensitization in the rat.
Hyperalgesia
NMDAR and JNK Activation in the Spinal Trigeminal Nucleus Caudalis Contributes to Masseter Hyperalgesia Induced by Stress.
Hyperalgesia
NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation.
Hyperalgesia
Pharmacological evidence for the participation of NO-cyclic GMP-PKG-K(+) channel pathway in the antiallodynic action of resveratrol.
Hyperalgesia
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia.
Hyperalgesia
Rapid development of nitric oxide-induced hyperalgesia depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model.
Hyperalgesia
Superoxide signaling in pain is independent of nitric oxide signaling.
Hyperalgesia
The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway.
Hyperalgesia
The role of systemic, spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice.
Hyperalgesia
The ruthenium nitric oxide donor, [Ru(HEDTA)NO], inhibits acute nociception in mice by modulating oxidative stress, cytokine production and activating the cGMP/PKG/ATP-sensitive potassium channel signaling pathway.
Hyperalgesia
TRPA1, NMDA receptors and nitric oxide mediate mechanical hyperalgesia induced by local injection of magnesium sulfate into the rat hind paw.
Hypercalcemia
Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia.
Hypercholesterolemia
Effect of hypercholesterolemia on expression and function of vascular soluble guanylyl cyclase.
Hypercholesterolemia
Hypercholesterolemia is associated with a reduced response of smooth muscle guanylyl cyclase to nitrovasodilators.
Hypercholesterolemia
The effect of hypercholesterolemia on platelet soluble guanylyl cyclase.
Hyperemia
Arginine analogues inhibit responses mediated by ATP-sensitive K+ channels.
Hyperemia
Changes in guanylate cyclase activity in arteriolar smooth muscle cells and hemodynamics after ischemia-reperfusion in rats.
Hyperemia
Hydrogen Peroxide-Dependent Arteriolar Dilation in Contracting Muscle of Rats Fed Normal and High Salt Diets.
Hyperemia
[Role of the endothelium in the development of reactive hyperemia]
Hyperemia
[The participation of humoral factors released by the endothelium in the development of reactive hyperemia]
Hyperglycemia
Effect of elevated glucose on cyclic GMP and eicosanoids produced by porcine aortic endothelium.
Hyperglycemia
Endothelium-dependent inhibition of Na(+)-K+ ATPase activity in rabbit aorta by hyperglycemia. Possible role of endothelium-derived nitric oxide.
Hyperkalemia
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Hyperlipidemias
Mechanisms underlying dysfunction of carotid arteries in genetically hyperlipidemic rabbits.
Hyperopia
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
Hypersensitivity
Distinct functions of soluble guanylyl cyclase isoforms NO-GC1 and NO-GC2 in inflammatory and neuropathic pain processing.
Hypersensitivity
Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
Hypersensitivity
Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice.
Hypersensitivity
Role of soluble guanylate cyclase in the trigeminal subnucleus caudalis in capsaicin-induced muscle hypersensitivity.
Hypersensitivity
Role of the haeme oxygenase/carbon monoxide pathway in mechanical nociceptor hypersensitivity.
Hypersensitivity
Spinal nNOS activation mediates sigma-1 receptor-induced mechanical and thermal hypersensitivity in mice: involvement of PKC-dependent NR1 phosphorylation.
Hypertension
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
Hypertension
A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug.
Hypertension
A-type natriuretic peptide receptor in the spontaneously hypertensive rat kidney.
Hypertension
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Hypertension
Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase.
Hypertension
Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats.
Hypertension
Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats.
Hypertension
Altered expression of vascular natriuretic peptide receptors in experimental hypertensive rats.
Hypertension
Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in angiotensin II-induced hypertension.
Hypertension
Alternative splicing of cGMP-dependent protein kinase I in angiotensin-hypertension: novel mechanism for nitrate tolerance in vascular smooth muscle.
Hypertension
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Hypertension
Androgen-sensitive hypertension associated with soluble guanylate cyclase-?1 deficiency is mediated by 20-HETE.
Hypertension
Angiotensin II-Induced Hypertension Is Attenuated by Reduction of Sympathetic Output in NO-Sensitive Guanylyl Cyclase 1 Knockout Mice.
Hypertension
Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Hypertension
Augmented S-nitrosylation contributes to impaired relaxation in angiotensin II hypertensive mouse aorta: role of thioredoxin reductase.
Hypertension
Blockers of the L-arginine-nitric oxide-cyclic GMP pathway facilitate baroreceptor resetting.
Hypertension
CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation in ANP-receptor deficient mice.
Hypertension
Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.
Hypertension
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hypertension
Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
Hypertension
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Hypertension
Comparison of the crystal structures and thermochemistry of a novel soluble guanylate cyclase stimulator riociguat and its solvates.
Hypertension
Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats.
Hypertension
Crosstalk between central pathways of nitric oxide and carbon monoxide in the hypertensive action of cyclosporine.
Hypertension
Differences between natriuretic peptide receptors in the olfactory bulb and hypothalamus from spontaneously hypertensive and normotensive rat brain.
Hypertension
Differentially-altered vascular guanylate cyclase isoforms in experimental hypertensive rats.
Hypertension
Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats.
Hypertension
Effect of methylene blue on blood pressure in rats.
Hypertension
Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney.
Hypertension
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Hypertension
Effects of Sevoflurane on Hemodynamics and Inducible Nitric Oxide Synthase/Soluble Guanylate Cyclase Signaling Pathway in a Rat Model of Pulmonary Arterial Hypertension.
Hypertension
Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.
Hypertension
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
Hypertension
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Hypertension
Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.
Hypertension
Evaluation of heterodimeric guanylyl cyclase genes as candidates for human hypertension.
Hypertension
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Hypertension
Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase.
Hypertension
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
Hypertension
Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.
Hypertension
Gene expression of brain nitric oxide synthase and soluble guanylyl cyclase in hypothalamus and medulla of two-kidney, one clip hypertensive rats.
Hypertension
Gene expression of natriuretic peptide receptors in rats with DOCA-salt hypertension.
Hypertension
Gene transfer of neuronal nitric oxide synthase into intracardiac Ganglia reverses vagal impairment in hypertensive rats.
Hypertension
Genetic mapping of soluble guanylyl cyclase genes: implications for linkage to blood pressure in the Dahl rat.
Hypertension
Genetic modifiers of hypertension in soluble guanylate cyclase ?1-deficient mice.
Hypertension
Human-antigen R (HuR) expression in hypertension: downregulation of the mRNA stabilizing protein HuR in genetic hypertension.
Hypertension
Hypertension reduces soluble guanylyl cyclase expression in the mouse aorta via the Notch signaling pathway.
Hypertension
Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination.
Hypertension
Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in carotid arteries from stroke-prone spontaneously hypertensive rats.
Hypertension
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Hypertension
In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat.
Hypertension
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor.
Hypertension
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hypertension
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Hypertension
Lead-induced hypertension: role of oxidative stress.
Hypertension
Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan.
Hypertension
Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.
Hypertension
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
Hypertension
Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy.
Hypertension
MLK3 mediates impact of PKG1? on cardiac function and controls blood pressure through separate mechanisms.
Hypertension
Molecular dissection of mouse soluble guanylyl cyclase alpha1 promoter.
Hypertension
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Hypertension
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Hypertension
NO-sensitive guanylyl cyclase in the lung.
Hypertension
Participation of nitric oxide and N-methyl-D-aspartic acid receptors in the pressor response to intrathecal injected noradrenaline at the spinal cord of the rat.
Hypertension
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Hypertension
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Hypertension
Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Hypertension
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Hypertension
Phosphorylation of atrial natriuretic factor R1 receptor by serine/threonine protein kinases: evidences for receptor regulation.
Hypertension
Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients.
Hypertension
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Hypertension
Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.
Hypertension
Renal atrial natriuretic peptide receptors binding properties and function are resistant to DOCA-salt-induced hypertension in rats.
Hypertension
Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib-Induced Hypertension.
Hypertension
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Hypertension
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Hypertension
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Hypertension
Riociguat for the treatment of pulmonary arterial hypertension.
Hypertension
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Hypertension
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Hypertension
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Hypertension
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Hypertension
Riociguat: a novel new drug for treatment of pulmonary hypertension.
Hypertension
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Hypertension
Riociguat: Clinical research and evolving role in therapy.
Hypertension
Riociguat: first global approval.
Hypertension
Roles of heme oxygenase/carbon monoxide system in genetically hypertensive rats.
Hypertension
Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide.
Hypertension
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis.
Hypertension
Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice.
Hypertension
Soluble guanylate cyclase contribute genetic susceptibility to essential hypertension in the Han Chinese population.
Hypertension
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats.
Hypertension
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis.
Hypertension
Soluble guanylate cyclase stimulator, trans-4-methoxy-?-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Hypertension
Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.
Hypertension
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hypertension
Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia.
Hypertension
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Hypertension
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Hypertension
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
Hypertension
The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling.
Hypertension
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
Hypertension
The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in rats.
Hypertension
The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus.
Hypertension
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Hypertension
Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice.
Hypertension
YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
Hypertension
YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
Hypertension
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
Hypertension
[Diagnosis and treatment of pulmonary hypertension].
Hypertension
[Doxazosin and soluble guanylate cyclase in a rat model of hypertension]
Hypertension
[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Hypertension, Portal
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Hypertension, Pregnancy-Induced
Impaired guanosine 3',5'-cyclic phosphate production in severe pregnancy-induced hypertension with high plasma levels of atrial and brain natriuretic peptides.
Hypertension, Pulmonary
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
Hypertension, Pulmonary
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Hypertension, Pulmonary
Acute Hemodynamic Effects of Riociguat in Patients with Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study.
Hypertension, Pulmonary
Analysis of responses to the Rho-kinase Inhibitor Y-27632 in the Pulmonary and Systemic Vascular Bed of the Rat.
Hypertension, Pulmonary
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Hypertension, Pulmonary
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Hypertension, Pulmonary
Atrial natriuretic peptide in hypoxia.
Hypertension, Pulmonary
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
Hypertension, Pulmonary
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats.
Hypertension, Pulmonary
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Hypertension, Pulmonary
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Hypertension, Pulmonary
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.
Hypertension, Pulmonary
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Hypertension, Pulmonary
Cinaciguat, a Soluble Guanylate Cyclase Activator, Augments cGMP after Oxidative Stress and Causes Pulmonary Vasodilation in Neonatal Pulmonary Hypertension.
Hypertension, Pulmonary
Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
Hypertension, Pulmonary
Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension.
Hypertension, Pulmonary
Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty.
Hypertension, Pulmonary
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Hypertension, Pulmonary
Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Hypertension, Pulmonary
Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS.
Hypertension, Pulmonary
Development of the normal and hypertensive pulmonary vasculature.
Hypertension, Pulmonary
Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator.
Hypertension, Pulmonary
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Hypertension, Pulmonary
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Hypertension, Pulmonary
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.
Hypertension, Pulmonary
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Hypertension, Pulmonary
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.
Hypertension, Pulmonary
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Hypertension, Pulmonary
Exposure of mice to chronic hypoxia attenuates pulmonary arterial contractile responses to acute hypoxia by increases in extracellular hydrogen peroxide.
Hypertension, Pulmonary
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
Hypertension, Pulmonary
Guanylate cyclase stimulators for pulmonary hypertension.
Hypertension, Pulmonary
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor.
Hypertension, Pulmonary
In vivo attenuation of endothelium-dependent pulmonary vasodilation by methylene blue.
Hypertension, Pulmonary
Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn.
Hypertension, Pulmonary
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Hypertension, Pulmonary
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.
Hypertension, Pulmonary
Interfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity.
Hypertension, Pulmonary
Medical management of chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.
Hypertension, Pulmonary
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Hypertension, Pulmonary
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Hypertension, Pulmonary
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
Hypertension, Pulmonary
Operability assessment in CTEPH: Lessons from the CHEST-1 study.
Hypertension, Pulmonary
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
Hypertension, Pulmonary
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam.
Hypertension, Pulmonary
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Hypertension, Pulmonary
Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.
Hypertension, Pulmonary
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Hypertension, Pulmonary
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Hypertension, Pulmonary
Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs.
Hypertension, Pulmonary
Redox regulation of responses to hypoxia and NO-cGMP signaling in pulmonary vascular pathophysiology.
Hypertension, Pulmonary
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Hypertension, Pulmonary
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Hypertension, Pulmonary
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Hypertension, Pulmonary
Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Hypertension, Pulmonary
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Hypertension, Pulmonary
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Hypertension, Pulmonary
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Hypertension, Pulmonary
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Hypertension, Pulmonary
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Hypertension, Pulmonary
Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Hypertension, Pulmonary
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Hypertension, Pulmonary
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Hypertension, Pulmonary
Riociguat: Clinical research and evolving role in therapy.
Hypertension, Pulmonary
Riociguat: first global approval.
Hypertension, Pulmonary
sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.
Hypertension, Pulmonary
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Hypertension, Pulmonary
Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor.
Hypertension, Pulmonary
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.
Hypertension, Pulmonary
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Hypertension, Pulmonary
Soluble Guanylate Cyclase Stimulators and Activators.
Hypertension, Pulmonary
Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension.
Hypertension, Pulmonary
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Stimulation of nitric oxide-sensitive soluble guanylate cyclase in monocrotaline-induced pulmonary hypertensive rats.
Hypertension, Pulmonary
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema.
Hypertension, Pulmonary
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Hypertension, Pulmonary
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
Hypertension, Pulmonary
The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs.
Hypertension, Pulmonary
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Hypertension, Pulmonary
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
Hypertension, Pulmonary
The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.
Hypertension, Pulmonary
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
Hypertension, Pulmonary
There is no substitute for experience: Lessons learned from CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) for future clinical trial design.
Hypertension, Pulmonary
Treatment of pulmonary hypertension.
Hypertension, Pulmonary
Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS.
Hypertension, Pulmonary
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Hypertension, Pulmonary
Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
Hypertension, Pulmonary
[Expression of PAI-2 mRNA in peripheral blood leucocytes and regulation by sGC activator in pulmonary hypertension].
Hypertension, Pulmonary
[Study on soluble guanylate cyclase in pulmonary hypertension rat model]
Hypertension, Pulmonary
[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Hypertension, Pulmonary
[The soluble guanylate cyclase stimulator riociguat is the first-line therapy for chronic thromboembolic pulmonary hypertension patients].
Hypertension, Renovascular
Natriuretic peptides buffer renin-dependent hypertension.
Hypertension, Renovascular
Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Hyperthyroidism
Altered role of C-type natriuretic peptide-activated pGC-cGMP-PDE3-cAMP signaling in hyperthyroid beating rabbit atria.
Hypertrophy, Left Ventricular
B-type natriuretic peptide receptors in hypertrophied adult rat cardiomyocytes.
Hypertrophy, Left Ventricular
Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy.
Hypertrophy, Left Ventricular
Increased guanylate cyclase activity is associated with an increase in cyclic guanosine 3',5'-monophosphate in left ventricular hypertrophy.
Hypertrophy, Left Ventricular
Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction.
Hypertrophy, Left Ventricular
Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts.
Hypertrophy, Left Ventricular
Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy.
Hypertrophy, Right Ventricular
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats.
Hypertrophy, Right Ventricular
Buffered l-ascorbic acid, alone or bound to KMUP-1 or sildenafil, reduces vascular endothelium growth factor and restores endothelium nitric oxide synthase in hypoxic pulmonary artery.
Hypertrophy, Right Ventricular
Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy.
Hypertrophy, Right Ventricular
The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
Hypertrophy, Right Ventricular
The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.
Hypoglycemia
Hypothalamic S-nitrosylation contributes to the counter-regulatory response impairment following recurrent hypoglycemia.
Hypotension
A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
Hypotension
Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
Hypotension
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
Hypotension
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Hypotension
Cyclosporine counteracts endotoxemia-evoked reductions in blood pressure and cardiac autonomic dysfunction via central sGC/MAPKs signaling in rats.
Hypotension
Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock.
Hypotension
Enhanced Hemeoxygenase Activity in the Rostral Ventrolateral Medulla Mediates the Exaggerated Hemin-Evoked Hypotension in the SHR.
Hypotension
Inhibition of and sensitization to the lethal effects of tumor necrosis factor.
Hypotension
Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model.
Hypotension
Mechanisms of atrial natriuretic factor-induced vasodilation.
Hypotension
Methylene blue and vasoplegia: who, when, and how?
Hypotension
Methylene blue reverses endotoxin-induced hypotension.
Hypotension
Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review.
Hypotension
Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery.
Hypotension
Modulation of cyclic guanosine monophosphate production during Escherichia coli septic shock.
Hypotension
N(G)-nitro-L-arginine methyl ester, but not methylene blue, attenuates anaphylactic hypotension in anesthetized mice.
Hypotension
Ophidian envenomation strategies and the role of purines.
Hypotension
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.
Hypotension
The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass.
Hypotension
The mast cell.
Hypotension
Vasorelaxation induced by a new naphthoquinone-oxime is mediated by NO-sGC-cGMP pathway.
Hypotension
[Does nitric oxide stress exist?]
Ileus
Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice.
Ileus
Jejunal cholinergic, nitrergic, and soluble guanylate cyclase activity in postoperative ileus.
Infections
Arabidopsis thaliana resistance to fusarium oxysporum 2 implicates tyrosine-sulfated peptide signaling in susceptibility and resistance to root infection.
Infections
Dirofilaria immitis: heartworm infection alters pulmonary artery endothelial cell behavior.
Infections
Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.
Infections
Evolutionarily distant pathogens require the Arabidopsis phytosulfokine signalling pathway to establish disease.
Infections
Identification of a Hippeastrum hybridum guanylyl cyclase responsive to wounding and pathogen infection.
Infections
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Infections
Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea.
Infections
Role of Porcine Aminopeptidase N and Sialic Acids in Porcine Coronavirus Infections in Primary Porcine Enterocytes.
Infections
The tyrosine-sulfated peptide receptors PSKR1 and PSY1R modify the immunity of Arabidopsis to biotrophic and necrotrophic pathogens in an antagonistic manner.
Infections
Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
Infertility
Preserved fertility despite erectile dysfunction in mice lacking the nitric oxide receptor.
Infertility, Female
Guanylate cyclase activity and sperm function.
Inflammatory Bowel Diseases
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
Inflammatory Bowel Diseases
Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C.
Inflammatory Bowel Diseases
Influence of soluble guanylate cyclase inhibition on inflammation and motility disturbances in DSS-induced colitis.
Inflammatory Bowel Diseases
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Insulin Resistance
? Cell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice.
Insulin Resistance
Decreased cyclic guanosine 3',5' monophosphate and guanylate cyclase activity in leprechaunism: evidence for a postreceptor defect.
Insulin Resistance
Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
Insulin Resistance
Hepatic guanylyl cyclase inhibition induces HISS-dependent insulin resistance.
Insulin Resistance
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Insulin Resistance
The Importance of Natriuretic Peptides in Cardiometabolic Diseases.
Insulinoma
Dominant negative mutants of nitric oxide-sensitive guanylyl cyclase.
Insulinoma
L-arginine stimulates cyclic guanosine 3',5'-monophosphate formation in rat islets of Langerhans and RINm5F insulinoma cells: evidence for L-arginine:nitric oxide synthase.
Insulinoma
Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells.
Intestinal Neoplasms
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Irritable Bowel Syndrome
A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.
Irritable Bowel Syndrome
Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
Irritable Bowel Syndrome
Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
Irritable Bowel Syndrome
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Irritable Bowel Syndrome
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Irritable Bowel Syndrome
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
Irritable Bowel Syndrome
UK clinical experience up to 52?weeks with linaclotide for irritable bowel syndrome with constipation.
Keratoconus
CRB1 GENE MUTATIONS ARE ASSOCIATED WITH KERATOCONUS IN PATIENTS WITH LEBER CONGENITAL AMAUROSIS.
Kidney Diseases
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Kidney Failure, Chronic
Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
Kidney Failure, Chronic
Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression.
Kidney Failure, Chronic
Medullar expression of type-A natriuretic peptide receptor in an animal model of hypertension induced by renal mass ablation.
Leber Congenital Amaurosis
A nonsense mutation in the retinal specific guanylate cyclase gene is the cause of Leber congenital amaurosis in a large inbred kindred from Jordan.
Leber Congenital Amaurosis
A novel mutation in the GUCY2D gene responsible for an early onset severe RP different from the usual GUCY2D-LCA phenotype.
Leber Congenital Amaurosis
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
Leber Congenital Amaurosis
Activation of retinal guanylyl cyclase RetGC1 by GCAP1: stoichiometry of binding and effect of new LCA-related mutations.
Leber Congenital Amaurosis
Complete abolition of the retinal-specific guanylyl cyclase (retGC-1) catalytic ability consistently leads to leber congenital amaurosis (LCA).
Leber Congenital Amaurosis
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.
Leber Congenital Amaurosis
Different functional outcome of RetGC1 and RPE65 gene mutations in Leber congenital amaurosis.
Leber Congenital Amaurosis
Evaluating the Role of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Domains in Binding Guanylyl Cyclase-activating Proteins (GCAPs).
Leber Congenital Amaurosis
Evidence of a founder effect for the RETGC1 (GUCY2D) 2943DelG mutation in Leber congenital amaurosis pedigrees of Finnish origin.
Leber Congenital Amaurosis
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
Leber Congenital Amaurosis
Functional analyses of mutant recessive GUCY2D alleles identified in Leber congenital amaurosis patients: protein domain comparisons and dominant negative effects.
Leber Congenital Amaurosis
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Leber Congenital Amaurosis
Insights gained from gene therapy in animal models of retGC1 deficiency.
Leber Congenital Amaurosis
Insights into the role of RD3 in guanylate cyclase trafficking, photoreceptor degeneration, and Leber congenital amaurosis.
Leber Congenital Amaurosis
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
Leber Congenital Amaurosis
RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis 12.
Leber Congenital Amaurosis
RD3, the protein associated with Leber congenital amaurosis type 12, is required for guanylate cyclase trafficking in photoreceptor cells.
Leber Congenital Amaurosis
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Leber Congenital Amaurosis
Variants at codon 838 in the GUCY2D gene result in different phenotypes of cone rod dystrophy.
Leukemia
Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Adenylate cyclase and guanylate cyclase activity in normal and leukemic human lymphocytes.
Leukemia, Myeloid, Acute
Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
Liver Cirrhosis
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.
Liver Cirrhosis
Brain regional alterations in the modulation of the glutamate-nitric oxide-cGMP pathway in liver cirrhosis. Role of hyperammonemia and cell types involved.
Liver Cirrhosis
Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications.
Liver Cirrhosis
Neurons exposed to ammonia reproduce the differential alteration in nitric oxide modulation of guanylate cyclase in the cerebellum and cortex of patients with liver cirrhosis.
Liver Cirrhosis
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Liver Cirrhosis
Single-Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell-Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice.
Liver Cirrhosis
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Cirrhosis, Biliary
Vasodilatory responses of isolated arteries of cirrhotic rats.
Liver Diseases
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.
Liver Diseases
Alterations in soluble guanylate cyclase content and modulation by nitric oxide in liver disease.
Liver Diseases
Altered modulation of soluble guanylate cyclase by nitric oxide in patients with liver disease.
Liver Diseases
Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease.
Liver Diseases
Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: a quantitative cytochemistry study.
Liver Diseases
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.
Liver Failure
Altered content and modulation of soluble guanylate cyclase in the cerebellum of rats with portacaval anastomosis.
Liver Failure
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients.
Liver Failure, Acute
Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure.
Liver Failure, Acute
In vivo evidence of enhanced guanylyl cyclase activation during the hyperdynamic circulation of acute liver failure.
Lordosis
A potential role of cyclic GMP in the regulation of lordosis behavior of female rats.
Lordosis
Evidence that the effect of melanocortins on female sexual behavior in preoptic area is mediated by the MC3 receptor; Participation of nitric oxide.
Lordosis
Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats.
Lordosis
The nitric oxide pathway participates in estrous behavior induced by progesterone and some of its ring A-reduced metabolites.
Lordosis
The nitric oxide pathway participates in lordosis behavior induced by central administration of leptin.
Lung Diseases
Therapeutic potential of soluble guanylate cyclase modulators in neonatal chronic lung disease.
Lung Diseases, Interstitial
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Lung Diseases, Interstitial
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
Lung Injury
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Lung Injury
Is nitric oxide released in oleic acid lung injury?
Lung Injury
L-arginine-dependent nitric oxide synthase: a new metabolic pathway in the lung and airways.
Lung Injury
Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury.
Lung Injury
Opposite effects of ANP receptors in attenuation of LPS-induced endothelial permeability and lung injury.
Lung Injury
Soluble guanylyl cyclase expression is reduced in LPS-induced lung injury.
Lung Injury
The role of natriuretic peptide receptor-A signaling in unilateral lung ischemia-reperfusion injury in the intact mouse.
Lung Injury
Transforming growth factor-beta down-regulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling.
Lung Neoplasms
Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2.
Lupus Erythematosus, Systemic
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Lymphatic Metastasis
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Lymphoma
Interferon enhances guanylate cyclase activity in human lymphoma cells.
Lymphoma
Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
Macular Degeneration
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Macular Degeneration
Mutation analysis at codon 838 of the Guanylate Cyclase 2D gene in Spanish families with autosomal dominant cone, cone-rod, and macular dystrophies.
Macular Degeneration
Two retinal dystrophy-associated missense mutations in GUCA1A with distinct molecular properties result in a similar aberrant regulation of the retinal guanylate cyclase.
Malaria
cGMP Signalling: Malarial Guanylyl Cyclase Leads the Way.
Malaria
Guanylyl cyclase activity associated with putative bifunctional integral membrane proteins in Plasmodium falciparum.
Malaria
PbGCbeta is essential for Plasmodium ookinete motility to invade midgut cell and for successful completion of parasite life cycle in mosquitoes.
Malaria
The gametocyte-activating factor xanthurenic acid stimulates an increase in membrane-associated guanylyl cyclase activity in the human malaria parasite Plasmodium falciparum.
Marfan Syndrome
Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO.
Meconium Ileus
Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C.
Melanoma
Differential expression of functional guanylyl cyclases in melanocytes: absence of nitric-oxide-sensitive isoform in metastatic cells.
Melanoma
Photoreceptor proteins as cancer-retina antigens.
Melanoma
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Melanoma
Stimulation of cyclic GMP efflux in human melanocytes by hypergravity generated by centrifugal acceleration.
Melanoma
Visible light modulates the expression of cancer-retina antigens.
Melanoma, Experimental
Natriuretic peptide receptor A as a novel target for cancer.
Memory Disorders
Hyperammonemia inhibits the natriuretic peptide receptor 2 (NPR-2)-mediated cyclic GMP synthesis in the astrocytic compartment of rat cerebral cortex slices.
Memory Disorders
In vivo exposure to carbon monoxide causes delayed impairment of activation of soluble guanylate cyclase by nitric oxide in rat brain cortex and cerebellum.
Memory Disorders
Mouse knockout of guanylyl cyclase C: Recognition memory deficits in the absence of activity changes.
Metabolic Syndrome
Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.
Metabolic Syndrome
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Metabolic Syndrome
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Metabolic Syndrome
Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: Implications in metabolic syndrome.
Metabolic Syndrome
Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome.
Metabolic Syndrome
Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
Migraine Disorders
Carnosine as a regulator of soluble guanylate cyclase.
Migraine Disorders
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
MPTP Poisoning
Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice.
Multiple Sclerosis
Cerebral and cerebellar guanylate cyclase activities in multiple sclerosis patients.
Multiple Sclerosis
Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains.
Muscle Spasticity
Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina.
Muscle Spasticity
Various pathogenetic factors revolving around the central role of protein kinase C activation in the occurrence of cerebral vasospasm
Muscular Diseases
Involvement of nitric oxide in nicotinic receptor-mediated myopathy.
Muscular Dystrophies
Guanylate cyclase activity in normal and diseased human muscle.
Muscular Dystrophy, Duchenne
Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.
Mycoses
The Hippeastrum hybridum PepR1 gene (HpPepR1) encodes a functional guanylyl cyclase and is involved in early response to fungal infection.
Mycoses
The tyrosine-sulfated peptide receptors PSKR1 and PSY1R modify the immunity of Arabidopsis to biotrophic and necrotrophic pathogens in an antagonistic manner.
Myocardial Infarction
Atrial natriuretic factor influences in vivo plasma, lung and aortic wall cGMP concentrations differently.
Myocardial Infarction
Cardioprotection by ischemic postconditioning and cGMP-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Myocardial Infarction
Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Myocardial Infarction
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Myocardial Infarction
Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure.
Myocardial Infarction
Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production.
Myocardial Infarction
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Myocardial Infarction
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Myocardial Ischemia
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs.
Myocardial Ischemia
Endothelium, coronary vasodilation, and organic nitrates.
Myocardial Ischemia
Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats.
Myocardial Ischemia
Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure.
Myocardial Ischemia
Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
Myocardial Ischemia
Soluble guanylate cyclase of platelets: function and regulation in normal and pathological states.
Myocardial Ischemia
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Myocardial Ischemia
[Soluble guanyl cyclase of blood platelets and heart of rats with experimental myocardial ischemia]
Myocardial Ischemia
[Soluble guanylate cyclase from rat platelets during experimental myocardial ischemia]
Myocarditis
[Comparison of guanylate cyclase activity of the heart and thrombocytes in normal states and in experimental allergic myocarditis]
Myoma
Estrogen receptor in human myoma tissue.
Nasal Polyps
Endothelial nitric oxide synthase/soluble guanylate cyclase system in human nasal polyps.
Nasal Polyps
Enzyme-ultracytochemical study of adenylate and guanylate cyclases in normal and pathologic human nasal mucosa.
Nematode Infections
Evolutionarily distant pathogens require the Arabidopsis phytosulfokine signalling pathway to establish disease.
Neoplasm Metastasis
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Neoplasm Metastasis
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes.
Neoplasm Metastasis
Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
Neoplasm Metastasis
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Neoplasm Metastasis
Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Neoplasm Metastasis
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Neoplasm Metastasis
Guanylyl cyclase C as a biomarker in colorectal cancer.
Neoplasm Metastasis
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Neoplasm Metastasis
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
Neoplasm Metastasis
Intrinsic variability in the detection of micrometastases in lymph nodes for re-staging of colorectal cancer. effect of individual markers and tissue samples.
Neoplasm Metastasis
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
Neoplasm Metastasis
Molecular staging of node negative patients with colorectal cancer.
Neoplasm Metastasis
Natriuretic peptide receptor A as a novel target for cancer.
Neoplasm Metastasis
Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
Neoplasm Metastasis
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Neoplasm Metastasis
[Detection of guanylate cyclase C mRNA and cytokeratin 20 mRNA in peripheral blood and analysis of prognosis in early to moderate colorectal cancer patients].
Neoplasm Micrometastasis
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
Neoplasm Micrometastasis
Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications.
Neoplasm Micrometastasis
Pathological staging and therapy of oesophageal and gastric cancer.
Neoplasm Micrometastasis
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Neoplasms
A role for PSK signaling in wounding and microbial interactions in Arabidopsis
Neoplasms
A role for PSK signaling in wounding and microbial interactions in Arabidopsis.
Neoplasms
Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance.
Neoplasms
Alterations in the subcellular distribution of Guanylate cyclase and its responsiveness to nitric oxide in diethylstilbestrol-induced renal tumors.
Neoplasms
An Analysis of the Multifaceted Roles of Heme in the Pathogenesis of Cancer and Related Diseases.
Neoplasms
Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.
Neoplasms
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer.
Neoplasms
Bile Acids Induce Ectopic Expression of Intestinal Guanylyl Cyclase C Through Nuclear Factor-kappaB and Cdx2 in Human Esophageal Cells.
Neoplasms
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Neoplasms
Biochemical evidence of cocarcinogenesis: tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity.
Neoplasms
C-type natriuretic peptide and its precursor: potential markers in human prostate cancer.
Neoplasms
Calcineurin Regulates Homologous Desensitization of Natriuretic Peptide Receptor-A and Inhibits ANP-Induced Testosterone Production in MA-10 Cells.
Neoplasms
Carnosine as a regulator of soluble guanylate cyclase.
Neoplasms
Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier.
Neoplasms
Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.
Neoplasms
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Neoplasms
Cyclic GMP and guanylate cyclase mediate lipopolysaccharide-induced Kupffer cell tumor necrosis factor-alpha synthesis.
Neoplasms
Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.
Neoplasms
Cyclic nucleotide metabolism in differentiated and undifferentiated epithelial thyroid cells in culture.
Neoplasms
Cyclic nucleotide metabolism in solid tumor tissues.
Neoplasms
Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs.
Neoplasms
Does stage II colorectal cancer need to be redefined?
Neoplasms
Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Neoplasms
Effect of lipoteichoic acid on dermal vascular permeability in mice.
Neoplasms
Endothelial-Specific Notch Blockade Inhibits Vascular Function and Tumor Growth through an eNOS-Dependent Mechanism.
Neoplasms
Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Neoplasms
Escherichia coli heat-stable toxin receptors in human colonic tumors.
Neoplasms
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Neoplasms
Functional multiplicity of atrial natriuretic peptide receptors on cultured rat Leydig tumor cells.
Neoplasms
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Neoplasms
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Neoplasms
Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer.
Neoplasms
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Neoplasms
Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
Neoplasms
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
Neoplasms
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
Neoplasms
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
Neoplasms
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
Neoplasms
GUCY2C ligand replacement to prevent colorectal cancer.
Neoplasms
Heme oxygenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts.
Neoplasms
Hydrogen peroxide alters splicing of soluble guanylyl cyclase and selectively modulates expression of splicing regulators in human cancer cells.
Neoplasms
Immunocapture-LC/MS-Based Target Engagement Measurement in Tumor Plasma Membrane.
Neoplasms
Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery.
Neoplasms
Impact of NPR-A expression in gastric cancer cells.
Neoplasms
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
Neoplasms
In vivo xenoestrogenic actions of cadmium and arsenic in anterior pituitary and uterus.
Neoplasms
Increased circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in persons with pheochromocytomas.
Neoplasms
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Neoplasms
Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3.
Neoplasms
Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).
Neoplasms
Inhibition of nitroso chemical carcinogen activation of rat hepatic guanylate cyclase by anticancer agents.
Neoplasms
Inhibition of proinflammatory tumor necrosis factor-{alpha}-induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in rat trachea: The involvement of soluble guanylate cyclase and protein kinase G.
Neoplasms
Intestinal GUCY2C Prevents TGF-? Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer.
Neoplasms
Intravasation-related metastatic factors in colorectal cancer.
Neoplasms
Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection.
Neoplasms
Lack of guanylyl cyclase C, the receptor for Escherichia coli heat-stable enterotoxin, results in reduced polyp formation and increased apoptosis in the multiple intestinal neoplasia (Min) mouse model.
Neoplasms
Mediation by nitric oxide formation in the preoptic area of endotoxin and tumour necrosis factor-induced inhibition of water intake in the rat.
Neoplasms
Molecular signature detection of circulating tumor cells using a panel of selected genes.
Neoplasms
Mucosally restricted antigens as novel immunological targets for antitumor therapy.
Neoplasms
Natriuretic peptide receptor A as a novel target for cancer.
Neoplasms
Natriuretic peptide receptors of type A in human neuroblastomas.
Neoplasms
Nitric oxide enhances PGI(2)production by human pulmonary artery smooth muscle cells.
Neoplasms
Nitric oxide suppresses the expression of Bcl-2 binding protein BNIP3 in hepatocytes.
Neoplasms
Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase.
Neoplasms
NPR-A: A Therapeutic Target in Inflammation and Cancer.
Neoplasms
Participation of the NO/cGMP/K+ATP pathway in the antinociception induced by Walker tumor bearing in rats.
Neoplasms
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.
Neoplasms
PGE2 and PGA2 affect the allosteric properties and the activities of calmodulin-dependent guanylate cyclase and Ca2+-stimulated ATPase of Walker-256 tumour microsomal membranes.
Neoplasms
Pharmacokinetics and Catabolism of [3H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate.
Neoplasms
Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B.
Neoplasms
Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Neoplasms
Previstage GCC Colorectal Cancer Staging Test: A New Molecular Test to Identify Lymph Node Metastases and Provide More Accurate Information about the Stage of Patients with Colorectal Cancer.
Neoplasms
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
Neoplasms
Properties of guanylate cyclase from rat kidney cortex and transplantable kidney tumors.
Neoplasms
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.
Neoplasms
PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours.
Neoplasms
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Neoplasms
Sex modulates intestinal transformation by the tumor-suppressor GCC.
Neoplasms
Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.
Neoplasms
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
Neoplasms
Soluble guanylyl cyclase ?1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.
Neoplasms
Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer.
Neoplasms
Studies on cyclic nucleotides in cancer. I. Adenylate guanylate cyclase and protein kinases in the prostatic sarcoma tissue.
Neoplasms
The First "Zero-Length" Mass Spectrometry-Cleavable Cross-Linker for Protein Structure Analysis.
Neoplasms
The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia.
Neoplasms
The paracrine hormone hypothesis of colorectal cancer.
Neoplasms
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
Neoplasms
The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review.
Neoplasms
Transforming growth factor beta 2 inhibits interleukin 1 beta- and tumour necrosis factor alpha-induction of nitric oxide synthase in rat renal mesangial cells.
Neoplasms
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Neoplasms
Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism.
Neoplasms
What is next in nitric oxide research? From cardiovascular system to cancer biology.
Neoplasms
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Neoplasms
[Guanyl cyclase and cyclic guanosine 3',5'-monosphate-phosphodiesterase in human cerebral tumors]
Neoplastic Cells, Circulating
Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Neuralgia
cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I.
Neuralgia
Distinct functions of soluble guanylyl cyclase isoforms NO-GC1 and NO-GC2 in inflammatory and neuropathic pain processing.
Neuralgia
Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat.
Neuralgia
Post-Transcriptional Regulation of Soluble Guanylate Cyclase that Governs Neuropathic Pain in Alzheimer's Disease.
Neuralgia
The nitric oxide-cyclic GMP pathway is required for nociceptive signalling at specific loci within the somatosensory pathway.
Neuralgia
The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.
Neurilemmoma
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Neuroblastoma
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one inhibits neurite outgrowth and causes neurite retraction in PC12 cells independently of soluble guanylyl cyclase.
Neuroblastoma
Activation by nitric oxide of guanylate cyclase in endothelial cells from brain capillaries.
Neuroblastoma
Activation of neuronal nitric oxide synthase by M2 muscarinic receptors associated with a small increase in intracellular calcium.
Neuroblastoma
Acute effects of ethanol and other short-chain alcohols on the guanylate cyclase system of murine neuroblastoma cells (clone N1E-115).
Neuroblastoma
Biological studies of a nitroso compound that releases nitric oxide upon illumination.
Neuroblastoma
CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line.
Neuroblastoma
Development of guanine analyzer to measure activity of guanylate cyclase.
Neuroblastoma
Differential coupling of m1, m3, and m5 muscarinic receptors to activation of neuronal nitric oxide synthase.
Neuroblastoma
Effects of arginine derivatives on soluble guanylate cyclase from neuroblastoma N1E 115 cells.
Neuroblastoma
Guanylate cyclase in neuroblastoma N1E 115 cells: presence of endogenous activator.
Neuroblastoma
Human A-type ANP receptor upregulation by PACAP and carbachol in neuroblastoma cells.
Neuroblastoma
Inhibition by lithium of cyclic GMP formation without inhibition of nitric oxide generation in the mouse neuroblastoma cell (N1E-115).
Neuroblastoma
L-Arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells.
Neuroblastoma
Methylene blue induces cytotoxicity in human brain tumor cells.
Neuroblastoma
N-hydroxylamine is not an intermediate in the conversion of L-arginine to an activator of soluble guanylate cyclase in neuroblastoma N1E-115 cells.
Neuroblastoma
Natriuretic peptide receptors of type A in human neuroblastomas.
Neuroblastoma
New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesis.
Neuroblastoma
Occupancy of muscarinic acetylcholine receptors stimulates a guanylate cyclase in neuroblastoma cells.
Neuroblastoma
Production and properties of antibody to soluble guanylate cyclase purified from bovine brain.
Neuroblastoma
Proliferative actions of natriuretic peptides on neuroblastoma cells. Involvement of guanylyl cyclase and non-guanylyl cyclase pathways.
Neuroblastoma
Receptor-mediated generation of an EDRF-like intermediate in a neuronal cell line detected by spin trapping techniques.
Neuroblastoma
Role of intracellular Ca2+ mobilization in muscarinic and histamine receptor-mediated activation of guanylate cyclase in N1E-115 neuroblastoma cells: assessment of the arachidonic acid release hypothesis.
Neuroblastoma
Selective activation of particulate guanylate cyclase by a specific class of porphyrins.
Neuroblastoma
The effect of unsaturated fatty acids on sodium nitroprusside stimulation of guanylate cyclase in the human astrocytoma clone, D384, and the human neuroblastoma clone, NB1-G.
Neurodegenerative Diseases
Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.
Neurodegenerative Diseases
Molecular docking analysis of phytoconstituent from Momordica charantia with Guanylate Cyclase catalytic domain.
Neurodegenerative Diseases
Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression.
Neurodegenerative Diseases
NO chimeras as therapeutic agents in Alzheimer's disease.
Neurodegenerative Diseases
The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases.
Neuromuscular Diseases
Guanylate cyclase activity in normal and diseased human muscle.
Night Blindness
GUCY2D mutations in retinal guanylyl cyclase 1 provide biochemical reasons for dominant cone-rod dystrophy but not for stationary night blindness.
Obesity
Defective development and microcirculation of intestine in Npr2 mutant mice.
Obesity
Effect of hereditary obesity on renal expressions of NO synthase, caveolin-1, AKt, guanylate cyclase, and calmodulin.
Obesity
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Obesity
Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Obesity
High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation.
Obesity
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
Obesity
Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes.
Obesity
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease.
Obesity
Pilot Study Measuring the Novel Satiety Hormone, Pro-Uroguanylin, in Adolescents With and Without Obesity.
Obesity
Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.
Obesity
Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding.
Obesity
Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue.
Obesity
The Importance of Natriuretic Peptides in Cardiometabolic Diseases.
Ocular Hypertension
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Oliguria
Guanylyl Cyclase A in Both Renal Proximal Tubular and Vascular Endothelial Cells Protects the Kidney against Acute Injury in Rodent Experimental Endotoxemia Models.
Opioid-Induced Constipation
Update on the management of constipation in the elderly: new treatment options.
Optic Nerve Diseases
Soluble Guanylate Cyclase ?1-Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma.
Osteoarthritis
cGMP levels in chronic cadmium disease and osteoarthritis.
Osteochondrodysplasias
C-type natriuretic peptide regulation of limb mesenchymal chondrogenesis is accompanied by altered N-cadherin and collagen type X-related functions.
Osteoporosis
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Osteoporosis
Soluble guanylate cyclase as a novel treatment target for osteoporosis.
Osteoporosis, Postmenopausal
Soluble guanylate cyclase as a novel treatment target for osteoporosis.
Ovarian Neoplasms
Impact of NPR-A expression in gastric cancer cells.
Ovarian Neoplasms
Natriuretic peptide receptor A as a novel target for cancer.
Ovarian Neoplasms
Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
Ovarian Neoplasms
Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Pancreatic Neoplasms
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Pancreatic Neoplasms
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.
Pancreatic Neoplasms
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Pancreatitis
Guanylate cyclase inhibition by methylene blue in circulatory shock caused by acute necrotizing pancreatitis: a word of caution based on a porcine model.
Pancreatitis
[Changes of guanylate cyclase C in colon tissues of rats with intestinal injury associated with severe acute pancreatitis].
Pancreatitis, Acute Necrotizing
Guanylate cyclase inhibition by methylene blue in circulatory shock caused by acute necrotizing pancreatitis: a word of caution based on a porcine model.
Papilloma
Guanylate cyclase activity in normal and neoplastic squamous epithelia from the upper aero-digestive tract.
Papilloma
Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP.
Parkinson Disease
Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression.
Parkinson Disease
Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease.
Parkinson Disease
Role of nitric oxide in the regulation of motor function. An overview of behavioral, biochemical and histological studies in animal models.
Parkinsonian Disorders
Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Periodontitis
[Adenylate cyclase and guanylate cyclase in the saliva of healthy persons and in periodontitis]
Peritoneal Fibrosis
Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice.
Pheochromocytoma
Activation of soluble guanylate cyclase through phosphorylation by protein kinase C in intact PC12 cells.
Pheochromocytoma
Increased circulating concentration of atrial natriuretic factor in persons with pheochromocytomas.
Pheochromocytoma
Increased circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in persons with pheochromocytomas.
Pheochromocytoma
Nerve growth factor decreases soluble guanylate cyclase in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells.
Pheochromocytoma
Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase.
Pheochromocytoma
Stimulation of the cyclic GMP pathway by NO induces expression of the immediate early genes c-fos and junB in PC12 cells.
Pheochromocytoma
[Studies on the cytological function of the biomembrane and the neurons]
Photophobia
Mg2+/Ca2+ cation binding cycle of guanylyl cyclase activating proteins (GCAPs): role in regulation of photoreceptor guanylyl cyclase.
Photophobia
Occupancy of the chromophore binding site of opsin activates visual transduction in rod photoreceptors.
Plasmacytoma
Manganese and magnesium dependent properties and inner plasma membrane surface localization of guanylate cyclase from murine plasmocytoma cells.
Porcine Reproductive and Respiratory Syndrome
DNA Sensing across the Tree of Life.
Porphyrias
Interactions of acetamide and acrylamide with heme models: Synthesis, infrared spectra, and solid state molecular structures of five- and six-coordinate ferric porphyrin derivatives.
Pre-Eclampsia
Aberrant pro-atrial natriuretic peptide/corin/natriuretic peptide receptor signaling is present in maternal vascular endothelium in preeclampsia.
Pre-Eclampsia
Atrial natriuretic peptide and sodium azide dependent guanylate cyclase activities in placentas from normal and severely toxemic patients.
Pre-Eclampsia
Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia.
Pre-Eclampsia
Endothelial Dysfunction in the Human Umbilical Artery due to Preeclampsia Can Be Prevented by Sildenafil.
Pre-Eclampsia
Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Pre-Eclampsia
Is Atrial Natriuretic Peptide (ANP) and Natriuretic Peptide Receptor-A (NPR-A) Expression in Human Placenta and Decidua Normal?
Pre-Eclampsia
Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre-eclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adenylate cyclase and guanylate cyclase activity in normal and leukemic human lymphocytes.
Premature Ejaculation
Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272.
Pressure Ulcer
A hopeful prospect of riociguat as a soluble guanylate cyclase stimulator for management of pressure ulcers.
Priapism
Alternative approaches to the management of priapism.
Primary Dysautonomias
Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.
Prostatic Hyperplasia
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Prostatic Neoplasms
A peptide against soluble guanylyl cyclase ?1: a new approach to treating prostate cancer.
Prostatic Neoplasms
Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.
Prostatic Neoplasms
cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines.
Prostatic Neoplasms
COP9 Subunits 4 and 5 Target Soluble Guanylyl Cyclase ?1 and p53 in Prostate Cancer Cells.
Prostatic Neoplasms
Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Inhibition of nitroso chemical carcinogen activation of rat hepatic guanylate cyclase by anticancer agents.
Prostatic Neoplasms
Peptide B targets soluble guanylyl cyclase ?1 and kills prostate cancer cells.
Prostatic Neoplasms
Soluble guanylyl cyclase ?1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.
Prostatic Neoplasms
The bradykinin/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells.
Prostatitis
Expression and Regulation of Brain Natriuretic Peptide and Natriuretic Peptide Receptor A (NPR-A) in L6-S1 Dorsal Root Ganglia in a Rat Model of Chronic Nonbacterial Prostatitis.
Prostatitis
[Expressions of BNP and NPR-A in rat models of chronic nonbacterial prostatitis and their significance].
Proteinuria
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Psoriasis
Cyclic GMP metabolism in psoriasis: activation of soluble epidermal guanylate cyclase by arachidonic acid and 12-hydroxy-5,8,10,14-eicosatetraenoic acid.
Pulmonary Arterial Hypertension
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Pulmonary Arterial Hypertension
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Pulmonary Arterial Hypertension
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Pulmonary Arterial Hypertension
Comparison of the crystal structures and thermochemistry of a novel soluble guanylate cyclase stimulator riociguat and its solvates.
Pulmonary Arterial Hypertension
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Pulmonary Arterial Hypertension
Effects of Sevoflurane on Hemodynamics and Inducible Nitric Oxide Synthase/Soluble Guanylate Cyclase Signaling Pathway in a Rat Model of Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
Pulmonary Arterial Hypertension
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Pulmonary Arterial Hypertension
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Pulmonary Arterial Hypertension
In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat.
Pulmonary Arterial Hypertension
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor.
Pulmonary Arterial Hypertension
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Pulmonary Arterial Hypertension
NO-sensitive guanylyl cyclase in the lung.
Pulmonary Arterial Hypertension
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Pulmonary Arterial Hypertension
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Pulmonary Arterial Hypertension
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Pulmonary Arterial Hypertension
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Pulmonary Arterial Hypertension
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Pulmonary Arterial Hypertension
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Pulmonary Arterial Hypertension
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Pulmonary Arterial Hypertension
Riociguat for the treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Pulmonary Arterial Hypertension
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Pulmonary Arterial Hypertension
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Pulmonary Arterial Hypertension
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Riociguat: a novel new drug for treatment of pulmonary hypertension.
Pulmonary Arterial Hypertension
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Riociguat: Clinical research and evolving role in therapy.
Pulmonary Arterial Hypertension
Riociguat: first global approval.
Pulmonary Arterial Hypertension
Soluble guanylate cyclase stimulator, trans-4-methoxy-?-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Pulmonary Arterial Hypertension
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Pulmonary Arterial Hypertension
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Pulmonary Arterial Hypertension
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Pulmonary Arterial Hypertension
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
Pulmonary Arterial Hypertension
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats.
Pulmonary Arterial Hypertension
The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in rats.
Pulmonary Arterial Hypertension
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Pulmonary Arterial Hypertension
YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
Pulmonary Arterial Hypertension
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
Pulmonary Arterial Hypertension
[Diagnosis and treatment of pulmonary hypertension].
Pulmonary Arterial Hypertension
[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Pulmonary Disease, Chronic Obstructive
Guanylyl Cyclase Activation Reverses Resistive Breathing-induced Lung Injury and Inflammation.
Pulmonary Disease, Chronic Obstructive
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.
Pulmonary Disease, Chronic Obstructive
Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
The Role of Soluble Guanylyl Cyclase in Chronic Obstructive Pulmonary Disease.
Pulmonary Edema
Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A.
Pulmonary Embolism
A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism.
Pulmonary Embolism
Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism.
Pulmonary Embolism
Pulmonary vascular reserve during experimental pulmonary embolism: Effects of a soluble guanylate cyclase stimulator, BAY 41-8543.
Pulmonary Embolism
Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism.
Pulmonary Fibrosis
NO-sensitive guanylyl cyclase in the lung.
Rectal Neoplasms
Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients.
Renal Insufficiency
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Renal Insufficiency
The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
Renal Insufficiency, Chronic
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.
Renal Insufficiency, Chronic
Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Renal Insufficiency, Chronic
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Renal Insufficiency, Chronic
The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
Reperfusion Injury
Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat.
Reperfusion Injury
Nitroglycerin reperfusion reduces ischemia-reperfusion injury in non-heart-beating donor lungs.
Reperfusion Injury
Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G.
Reperfusion Injury
Protein kinase A dependent signalling mediates anti-apoptotic effects of the atrial natriuretic peptide in ischemic livers.
Reperfusion Injury
Soluble guanylate cyclase-{alpha}1 is required for the cardioprotective effects of inhaled nitric oxide.
Reperfusion Injury
The Carbon monoxide releasing molecule ALF-186 mediates anti-inflammatory and neuroprotective effects via the soluble guanylate cyclase ß1 in rats' retinal ganglion cells after ischemia and reperfusion injury.
Reperfusion Injury
Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.
Reperfusion Injury
Urodilatin limits acute reperfusion injury in the isolated rat heart.
Respiratory Distress Syndrome
NO-sensitive guanylyl cyclase in the lung.
Retinal Degeneration
A null mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype.
Retinal Degeneration
Accumulation of calcium in degenerating photoreceptors of several Drosophila mutants.
Retinal Degeneration
Chemical shift assignments of retinal degeneration 3 protein (RD3).
Retinal Degeneration
Constitutive excitation by Gly90Asp rhodopsin rescues rods from degeneration caused by elevated production of cGMP in the dark.
Retinal Degeneration
Dimerization Domain of Retinal Membrane Guanylyl Cyclase 1 (RetGC1) Is an Essential Part of Guanylyl Cyclase-activating Protein (GCAP) Binding Interface.
Retinal Degeneration
Dominant Cone-Rod Dystrophy: A Mouse Model Generated by Gene Targeting of the GCAP1/Guca1a Gene.
Retinal Degeneration
Dysfunction of outer segment guanylate cyclase caused by retinal disease related mutations.
Retinal Degeneration
Functional Study and Mapping Sites for Interaction with the Target Enzyme in Retinal Degeneration 3 (RD3) Protein.
Retinal Degeneration
Genetic expression of cyclic GMP phosphodiesterase activity defines abnormal photoreceptor differentiation in neurological mutants of inherited retinal degeneration.
Retinal Degeneration
Increased light exposure alleviates one form of photoreceptor degeneration marked by elevated calcium in the dark.
Retinal Degeneration
Methylene Blue Prevents Retinal Damage Caused by Perinatal Asphyxia in the Rat.
Retinal Degeneration
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy.
Retinal Degeneration
Novel GUCA1A Mutations Suggesting Possible Mechanisms of Pathogenesis in Cone, Cone-Rod, and Macular Dystrophy Patients.
Retinal Degeneration
Phosphoinositide Metabolism in Drosophila Phototransduction: A Coffee Break Discussion Leads to 30 Years of History.
Retinal Degeneration
Retinal degeneration 3 (RD3) protein inhibits catalytic activity of retinal membrane guanylyl cyclase (RetGC) and its stimulation by activating proteins.
Retinal Degeneration
Retinal degeneration 3 (RD3) protein, a retinal guanylyl cyclase regulator, forms a monomeric and elongated four-helix bundle.
Retinal Degeneration
Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights.
Retinal Degeneration
Retinal degeneration-3 protein attenuates photoreceptor degeneration in transgenic mice expressing dominant mutation of human retinal guanylyl cyclase.
Retinal Diseases
Bicarbonate Modulates Photoreceptor Guanylate Cyclase (ROS-GC) Catalytic Activity.
Retinal Diseases
Dysfunction of outer segment guanylate cyclase caused by retinal disease related mutations.
Retinal Diseases
Enzymatic relay mechanism stimulates cyclic GMP synthesis in rod photoresponse: biochemical and physiological study in guanylyl cyclase activating protein 1 knockout mice.
Retinal Diseases
Factors that affect regulation of cGMP synthesis in vertebrate photoreceptors and their genetic link to human retinal degeneration.
Retinal Diseases
First 3D-Structural Data of Full-Length Guanylyl Cyclase 1 in Rod-Outer-Segment Preparations of Bovine Retina by Cross-Linking/Mass Spectrometry.
Retinal Diseases
Human retinal guanylate cyclase (GUC2D) maps to chromosome 17p13.1.
Retinal Diseases
Identification of Target Binding Site in Photoreceptor Guanylyl Cyclase-activating Protein 1 (GCAP1).
Retinal Diseases
Involvement of rhodopsin and ATP in the activation of membranous guanylate cyclase in retinal photoreceptor outer segments (ROS-GC) by GC-activating proteins (GCAPs): a new model for ROS-GC activation and its link to retinal diseases.
Retinal Diseases
Localisation of a gene for central areolar choroidal dystrophy to chromosome 17p.
Retinal Diseases
Regulation of cGMP synthesis in photoreceptors: role in signal transduction and congenital diseases of the retina.
Retinal Diseases
Retinal diseases linked with photoreceptor guanylate cyclase.
Retinal Dystrophies
A decrease in guanylate cyclase activity in some tissues of C3H/HeJ mice with retinal dystrophy.
Retinal Dystrophies
Activation of retinal guanylyl cyclase RetGC1 by GCAP1: stoichiometry of binding and effect of new LCA-related mutations.
Retinal Dystrophies
Functional analyses of mutant recessive GUCY2D alleles identified in Leber congenital amaurosis patients: protein domain comparisons and dominant negative effects.
Retinal Dystrophies
Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.
Retinal Dystrophies
Impaired Association of Retinal Degeneration-3 with Guanylate Cyclase-1 and Guanylate Cyclase-activating Protein-1 Leads to Leber Congenital Amaurosis-1.
Retinal Dystrophies
Insights gained from gene therapy in animal models of retGC1 deficiency.
Retinal Dystrophies
Membrane guanylate cyclase, a multimodal transduction machine: history, present, and future directions.
Retinal Dystrophies
Organization of the canine gene encoding the E isoform of retinal guanylate cyclase (cGC-E) and exclusion of its involvement in the inherited retinal dystrophy of the Swedish Briard and Briard-beagle dogs.
Retinal Dystrophies
Photoreceptor Guanylate Cyclase (GUCY2D) Mutations Cause Retinal Dystrophies by Severe Malfunction of Ca2+-Dependent Cyclic GMP Synthesis.
Retinal Dystrophies
Reanalysis of Association of Pro50Leu Substitution in Guanylate Cyclase Activating Protein-1 With Dominant Retinal Dystrophy.
Retinitis Pigmentosa
Cone dystrophy or macular dystrophy associated with novel autosomal dominant GUCA1A mutations.
Retinitis Pigmentosa
Mutations that are a common cause of Leber congenital amaurosis in northern America are rare in Southern India.
Retinitis Pigmentosa
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy.
Retinitis Pigmentosa
shRNA knockdown of guanylate cyclase 2e or cyclic nucleotide gated channel alpha 1 increases photoreceptor survival in a cGMP phosphodiesterase mouse model of retinitis pigmentosa.
Sarcoma
Guanylate cyclase and cyclic guanosine 3':5'-monophosphate phosphodiesterase activities and cyclic guanosine 3':5'-monophosphate levels in normal and transformed fibroblasts in culture.
Sarcoma
Studies on cyclic nucleotides in cancer. I. Adenylate guanylate cyclase and protein kinases in the prostatic sarcoma tissue.
Scleroderma, Systemic
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Scleroderma, Systemic
Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.
Scleroderma, Systemic
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis.
Scleroderma, Systemic
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat.
Scleroderma, Systemic
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
Seizures
Involvement of nNOS, and ?1, ?2, ?1, and ?2 Subunits of Soluble Guanylyl Cyclase Genes Expression in Anticonvulsant Effect of Sumatriptan on Pentylenetetrazole-Induced Seizure in Mice.
Seizures
L-arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex.
Seizures
Nitric oxide: an endogenous anticonvulsant substance.
Seizures
Protective effect of NG-nitro-L-arginine (N5-[imino(nitroamino)methyl]-L-ornithine) against cyanide-induced convulsions in mice.
Seizures
Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure.
Seizures
Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice.
Seizures
Sodium nitroprusside-induced seizure and taurine release from rat hippocampus.
Sepsis
Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue.
Sepsis
C-Type Natriuretic Peptide Induces Anti-contractile Effect Dependent on Nitric Oxide, Oxidative Stress, and NPR-B Activation in Sepsis.
Sepsis
Carnosine as a regulator of soluble guanylate cyclase.
Sepsis
Decreased aortic smooth muscle contraction in a rat model of multibacterial sepsis.
Sepsis
Heme oxygenase-dependent carbon monoxide production is a hepatic adaptive response to sepsis.
Sepsis
INHIBITION OF GUANYLYL CYCLASE RESTORES NEUTROPHIL MIGRATION AND MAINTAINS BACTERICIDAL ACTIVITY INCREASING SURVIVAL IN SEPSIS.
Sepsis
Ionic imbalance and lack of effect of adjuvant treatment with methylene blue in the hamster model of leptospirosis.
Sepsis
Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model.
Sepsis
Neuronal Nitric Oxide Synthase and Its Interaction With Soluble Guanylate Cyclase Is a Key Factor for the Vascular Dysfunction of Experimental Sepsis.
Sepsis
Nitric oxide and cardiovascular dysfunction in sepsis.
Sepsis
Nitric oxide and vascular reactivity in sepsis.
Sepsis
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.
Sepsis
Role of central NO-cGMP pathway in vasopressin and oxytocin gene expression during sepsis.
Sepsis
Role of Methylene Blue in the Maintenance of Postinduction Hemodynamic Status in Patients with Perforation Peritonitis: A Pilot Study.
Sepsis
sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models.
Sepsis
The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review.
Shock, Septic
Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue.
Shock, Septic
Carnosine as a regulator of soluble guanylate cyclase.
Shock, Septic
Differential effects of a selective inhibitor of soluble guanylyl cyclase on global and regional hemodynamics during canine endotoxic shock.
Shock, Septic
Does methylene blue administration to septic shock patients affect vascular permeability and blood volume?
Shock, Septic
Effect of methylene blue on middle cerebral artery flow velocity in a patient with severe sepsis following clipping of a cerebral aneurysm.
Shock, Septic
Effect of methylene blue on refractory neonatal hypotension.
Shock, Septic
Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.
Shock, Septic
Methylene blue administration in septic shock: a clinical trial.
Shock, Septic
Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations.
Shock, Septic
Methylene blue reverses endotoxin-induced hypotension.
Shock, Septic
Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats.
Shock, Septic
Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility.
Shock, Septic
The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock.
Shock, Septic
[Does nitric oxide stress exist?]
Spasm
Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure.
Spasm
Suppression of Graft Spasm by the Particulate Guanylyl Cyclase Activator in Coronary Bypass Surgery.
Squamous Cell Carcinoma of Head and Neck
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma.
Starvation
Guanylate cyclase activity in rat liver and other tissues with starvation and streptozotocin-induced diabetes mellitus.
Starvation
Nitric oxide synthase is induced in sporulation of Physarum polycephalum.
Starvation
Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes.
Status Epilepticus
Influence of lesions of the noradrenergic locus coeruleus system on the cerebral metabolic response to bicuculline-induced seizures.
Stomach Diseases
The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage.
Stomach Neoplasms
Atrial natriuretic peptide modulates the proliferation of human gastric cancer cells via KCNQ1 expression.
Stomach Neoplasms
Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.
Stomach Neoplasms
Ectopic expression of guanylyl cyclase C in gastric cancer as a potential biomarker and therapeutic target.
Stomach Neoplasms
Impact of NPR-A expression in gastric cancer cells.
Stomach Neoplasms
[Expression of guanylyl cyclase-c and caudal type homeobox transcription factor 2 in human gastric cancer and precursor lesions]
Stroke
Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
Stroke
Nitric oxide modulates cardiac performance in the heart of Anguilla anguilla.
Stroke
Nitric oxide modulates the frog heart ventricle morphodynamics.
Stroke
Soluble guanylate cyclase alpha1beta1 limits stroke size and attenuates neurological injury.
Stroke
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Subarachnoid Hemorrhage
Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys.
Subarachnoid Hemorrhage
Nitric oxide synthase and guanylate cyclase levels in canine basilar artery after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage.
Tachycardia
Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Tachycardia
Hemin blunts the depressant effect of chronic nicotine on reflex tachycardia via activation of central NOS/PI3K pathway in female rats.
Tachycardia
Nitric oxide in the insular cortex modulates baroreflex responses in a cGMP-independent pathway.
Tetanus
Mice deficient in endothelial nitric oxide synthase exhibit a selective deficit in hippocampal long-term potentiation.
Tetanus
On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus.
Tetanus
Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia.
Tetanus
Synaptic transmission in neurons that express the Drosophila atypical soluble guanylyl cyclases, Gyc-89Da and Gyc-89Db, is necessary for the successful completion of larval and adult ecdysis.
Thrombocytopenia
Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer.
Thromboembolism
In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictor.
Thrombosis
Cardiovascular consequences when nitric oxide and lipid signaling converge.
Thrombosis
Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains.
Thrombosis
Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure.
Thrombosis
YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.
Toxemia
Atrial natriuretic peptide and sodium azide dependent guanylate cyclase activities in placentas from normal and severely toxemic patients.
Trigeminal Neuralgia
Involvement of the BNP/NPR-A/BKCa pathway in rat trigeminal ganglia following chronic constriction injury.
Tuberculosis
Drug discovery targeting heme-based sensors and their coupled activities.
Tuberculosis, Pulmonary
[Guanylate cyclase from human platelets in pulmonary tuberculosis]
Uremia
Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia.
Ureteral Obstruction
Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction.
Ureteral Obstruction
Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction.
Ureteral Obstruction
Unilateral ureteral obstruction increases glomerular soluble guanylyl cyclase activity.
Urethral Obstruction
Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Urinary Bladder, Overactive
The Soluble Guanylyl Cyclase Activator BAY 60-2770 Ameliorates Overactive Bladder in Obese Mice.
Urinary Tract Infections
Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
Urogenital Diseases
Stimulators and activators of soluble guanylate cyclase for urogenital disorders.
Vascular Diseases
Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Vascular Diseases
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Vascular Diseases
Oxidant-redox regulation of pulmonary vascular responses to hypoxia and nitric oxide-cGMP signaling.
Vascular Diseases
Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.
Vascular Diseases
Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Vascular Diseases
Sphingosine-1-phosphate inhibits C-type natriuretic peptide activation of guanylyl cyclase B (GC-B/NPR-B).
Vascular Ring
Disturbances in ex vivo vascular smooth muscle responses following exposure to Pasteurella haemolytica vaccines.
Vascular Ring
Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation.
Vascular Ring
Isoflurane does not vasodilate rat thoracic aortic rings by endothelium-derived relaxing factor or other cyclic GMP-mediated mechanisms.
Vascular Ring
The Lignan (-)-Cubebin Inhibits Vascular Contraction and Induces Relaxation Via Nitric Oxide Activation in Isolated Rat Aorta.
Vascular System Injuries
Cygnets: in vivo characterization of novel cGMP indicators and in vivo imaging of intracellular cGMP.
Vascular System Injuries
Gender-Specific Modulation of the Response to Arterial Injury by Soluble Guanylate Cyclase alpha1.
Vasoplegia
Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment.
Vasoplegia
Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis.
Vasoplegia
Intraoperative vasoplegia: methylene blue to the rescue!
Vasoplegia
Methylene blue and vasoplegia: who, when, and how?
Vasoplegia
Methylene Blue for Vasoplegia When on Cardiopulmonary Bypass During Double-Lung Transplantation.
Vasoplegia
Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties.
Vasoplegia
Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery.
Vasoplegia
Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?
Vasoplegia
Role of Methylene Blue in the Maintenance of Postinduction Hemodynamic Status in Patients with Perforation Peritonitis: A Pilot Study.
Vasoplegia
The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review.
Vasoplegia
[Adult cardiopulmonary bypass in the twentieth century: science, art or empiricism?]
Vasospasm, Intracranial
Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage.
Ventilator-Induced Lung Injury
Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice.
Ventricular Dysfunction, Left
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Ventricular Fibrillation
An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart.
Virus Diseases
In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat.
Virus Diseases
Viral respiratory infection increases alveolar macrophage cytoplasmic motility in rats: role of NO.
Vision Disorders
Spectrum of retGC1 mutations in Leber's congenital amaurosis.
Whooping Cough
Acidification of serotonin-containing secretory vesicles induced by a plasma membrane calcium receptor.
Whooping Cough
Activation of guanylate cyclase by E. coli heat-stable enterotoxin (STa). Modulation by NAD and pertussis toxin.
Whooping Cough
Adenosine 5'-triphosphate, phorbol ester, and pertussis toxin effects on atrial natriuretic peptide stimulation of guanylate cyclase in a human renal cell line.
Whooping Cough
Alterations in inotropy, nitric oxide and cyclic GMP synthesis, protein phosphorylation and ADP-ribosylation in the endotoxin-treated rat myocardium and cardiomyocytes.
Whooping Cough
Binding of regulatory subunits of cyclic AMP-dependent protein kinase to cyclic CMP agarose.
Whooping Cough
C-type natriuretic peptide neuromodulates via "clearance" receptors.
Whooping Cough
Cardiac role of frog ANF: negative inotropism and binding sites in Rana esculenta.
Whooping Cough
Does cyclic guanosine monophosphate mediate noradrenaline-induced inhibition of islet insulin secretion stimulated by glucose and palmitate?
Whooping Cough
Failure of pertussis toxin to inhibit activation of guanylate cyclase by the heat-stable enterotoxin of Escherichia coli (STa) in the T84 cell line.
Whooping Cough
G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor.
Whooping Cough
G-protein-sensitive guanylyl cyclase activity associated with plasma membranes.
Whooping Cough
Ghrelin signalling in guinea-pig femoral artery smooth muscle cells.
Whooping Cough
Guanylin, uroguanylin, and heat-stable euterotoxin activate guanylate cyclase C and/or a pertussis toxin-sensitive G protein in human proximal tubule cells.
Whooping Cough
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.
Whooping Cough
Novel isoforms of Mel1c melatonin receptors modulating intracellular cyclic guanosine 3',5'-monophosphate levels.
Whooping Cough
Pancreastatin activates pertussis toxin-sensitive guanylate cyclase and pertussis toxin-insensitive phospholipase C in rat liver membranes.
Whooping Cough
Pertussis toxin inhibits endothelium-dependent relaxations evoked by fluoride.
Whooping Cough
Solubilization and reprecipitation from intestinal brush border membranes of a complex containing guanylate cyclase activatable by the heat-stable enterotoxin.
Whooping Cough
The opposing effects of calmodulin, adenosine 5'-triphosphate, and pertussis toxin on phorbol ester induced inhibition of atrial natriuretic factor stimulated guanylate cyclase in SK-NEP-1 cells.
Whooping Cough
Transmembrane signalling of atrial natriuretic peptide in rat renal juxtaglomerular cells.
Whooping Cough
Two opposite signal transducing mechanisms regulate a G-protein-coupled guanylyl cyclase.
Yersinia Infections
[Prostaglandins and cyclic nucleotides in the gastrointestinal form of yersiniosis]
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.